{
    "drugSuccessPredictions": [
      {
        "drugId": "6259",
        "displayName": "tocilizumab (intravenous), Roche/Chugai",
        "drugPrograms": [
          {
            "company": {
              "id": "15414",
              "name": "Chugai Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "2887",
              "name": "Polymyalgia rheumatica"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Jul-2012",
            "endDate": "",
            "statusDate": "24-Jul-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "24-Jul-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15414",
              "name": "Chugai Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3244",
              "name": "Familial Mediterranean fever"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "23-Apr-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15414",
              "name": "Chugai Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "15414",
              "name": "Chugai Pharmaceutical Co Ltd"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "212",
              "name": "Motor neurone disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2015",
            "endDate": "",
            "statusDate": "30-Nov-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Nov-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "245",
              "name": "Osteoarthritis"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Nov-2016",
            "endDate": "",
            "statusDate": "27-Nov-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "27-Nov-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "318",
              "name": "Systemic lupus erythematosus"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Feb-2003",
            "endDate": "",
            "statusDate": "26-Feb-2003",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Feb-2003",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1734",
              "name": "Chronic lymphocytic leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jun-2015",
            "endDate": "13-Mar-2031",
            "statusDate": "26-Jun-2015",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "7.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Jun-2015",
                "endDate": "01-Jul-2025",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2025",
                "endDate": "12-Aug-2027",
                "successPercentage": "31%",
                "predictedDateL50": "09-Jun-2024",
                "predictedDateU50": "14-Jun-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "12-Aug-2027",
                "endDate": "04-Mar-2030",
                "successPercentage": "47%",
                "predictedDateL50": "20-Jul-2026",
                "predictedDateU50": "19-Jan-2028",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Mar-2030",
                "endDate": "03-Feb-2031",
                "successPercentage": "62%",
                "predictedDateL50": "23-Jan-2029",
                "predictedDateU50": "18-Jul-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Feb-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Oct-2030",
                "predictedDateU50": "13-Mar-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1818",
              "name": "Viral pneumonia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Apr-2020",
            "endDate": "",
            "statusDate": "31-Jan-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-Apr-2020",
                "endDate": "31-Jan-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jan-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3244",
              "name": "Familial Mediterranean fever"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "23-Apr-2018",
            "endDate": "22-Aug-2027",
            "statusDate": "23-Apr-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Apr-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "24-Aug-2026",
                "successPercentage": "42%",
                "predictedDateL50": "02-Apr-2023",
                "predictedDateU50": "26-Jun-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Aug-2026",
                "endDate": "14-Jul-2027",
                "successPercentage": "88%",
                "predictedDateL50": "06-Jul-2025",
                "predictedDateU50": "01-Feb-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "03-Apr-2027",
                "predictedDateU50": "22-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "06-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, positive data were reported for the phase II study (NCT03446209) in 30 patients with Familial Mediterranean Fever which showed that the trial met its co-primary endpoints. The primary endpoint of number of patients achieving an adequate response to treatment at week 16, defined as a PGA &lt;/= 2 + normalized erythrocyte sedimentation rate or CRP + normalized serum amyloid A (SAA), was met by only two tocilizumab-treated patients at week 16, but none in the placebo arm (p = 0.089). Significant difference in PGA was not observed [ <ulink linkID=\"2561831\" linkType=\"Reference\">  2561831 </ulink>], [ <ulink linkID=\"2563528\" linkType=\"Reference\">  2563528 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "06-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, top-line data of a phase II study (NCT03446209) in 30 patients with Familial Mediterranean Fever were presented. The primary endpoint of number of patients achieving an adequate response to treatment at week 16, defined as a PGA &lt;/= 2 + normalized erythrocyte sedimentation rate or CRP + normalized serum amyloid A (SAA), was met by only two tocilizumab-treated patients at week 16, but none in the placebo arm (p = 0.089). Significant difference in PGA was not observed [ <ulink linkID=\"2561831\" linkType=\"Reference\">  2561831 </ulink>], [ <ulink linkID=\"2563528\" linkType=\"Reference\">  2563528 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2023",
            "endDate": "10-Oct-2029",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jun-2023",
                "endDate": "03-May-2026",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-May-2026",
                "endDate": "23-Nov-2028",
                "successPercentage": "33%",
                "predictedDateL50": "12-Jun-2025",
                "predictedDateU50": "06-Sep-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Nov-2028",
                "endDate": "10-Sep-2029",
                "successPercentage": "68%",
                "predictedDateL50": "15-Oct-2027",
                "predictedDateU50": "08-Apr-2029",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-May-2029",
                "predictedDateU50": "10-Oct-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "03-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, a phase Ib/II trial (NCT03424005) was expected to complete in May 2026 [ <ulink linkID=\"2373651\" linkType=\"Reference\"> 2046973 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Jun-2023",
            "endDate": "11-Dec-2029",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "09-Jun-2023",
                "endDate": "03-May-2026",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-May-2026",
                "endDate": "23-Nov-2028",
                "successPercentage": "35%",
                "predictedDateL50": "12-Jun-2025",
                "predictedDateU50": "06-Sep-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Nov-2028",
                "endDate": "30-Oct-2029",
                "successPercentage": "66%",
                "predictedDateL50": "15-Oct-2027",
                "predictedDateU50": "08-Apr-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Oct-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Jul-2029",
                "predictedDateU50": "11-Dec-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "03-May-2026",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, a phase Ib/II trial (NCT03424005) was expected to complete in May 2026 [ <ulink linkID=\"2373651\" linkType=\"Reference\"> 2046973 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "7237",
        "displayName": "denileukin diftitox",
        "drugPrograms": [
          {
            "company": {
              "id": "1077492",
              "name": "Citius Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1754",
              "name": "Cutaneous T-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "28-Sep-2022",
            "endDate": "02-Mar-2024",
            "statusDate": "28-Sep-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "28-Sep-2022",
                "endDate": "01-Feb-2024",
                "successPercentage": "24%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "02-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "28-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the updated PDUFA target action date was set for July 28, 2023 [ <ulink linkID=\"2797709\" linkType=\"Reference\"> 2797709 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "29-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the US FDA issued a Complete Response Letter regarding BLA application for LYMPHIR for the treatment of relapsed or refractory cutaneous T-cell lymphoma [ <ulink linkID=\"3028558\" linkType=\"Reference\"> 3028558 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "28-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the PDUFA target action date was set for September 28, 2023 [ <ulink linkID=\"2783590\" linkType=\"Reference\">  2783590 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Mar-2024",
                "notes": "In September 2023, BLA resubmission to the US FDA was planned in early 2024 [ <ulink linkID=\"3115168\" linkType=\"Reference\"> 3115168 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Apr-2010",
            "endDate": "06-Jul-2031",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "7.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2010",
                "endDate": "16-Dec-2027",
                "successPercentage": "40%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "17.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2027",
                "endDate": "27-Jul-2030",
                "successPercentage": "57%",
                "predictedDateL50": "04-Apr-2027",
                "predictedDateU50": "09-Sep-2028",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Jul-2030",
                "endDate": "27-May-2031",
                "successPercentage": "77%",
                "predictedDateL50": "09-Jun-2029",
                "predictedDateU50": "17-Dec-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Feb-2031",
                "predictedDateU50": "06-Jul-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "31-Dec-2027",
                "notes": "In October 2022, phase I/II trial (NCT05200559) of E-7777 in combination with pembrolizumab in metastatic solid tumor patients was expected to complete in December 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2022",
            "endDate": "28-Aug-2030",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "6.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2022",
                "endDate": "16-Jan-2027",
                "successPercentage": "59%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Jan-2027",
                "endDate": "22-Sep-2029",
                "successPercentage": "62%",
                "predictedDateL50": "08-Jun-2026",
                "predictedDateU50": "12-May-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Sep-2029",
                "endDate": "22-Jul-2030",
                "successPercentage": "84%",
                "predictedDateL50": "02-Aug-2028",
                "predictedDateU50": "23-Feb-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jul-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2030",
                "predictedDateU50": "28-Aug-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jan-2027",
                "milestoneExtendedDate": "31-Jan-2027",
                "notes": "In January 2022,  a phase I/II study (NCT05200559) was expected to complete in January 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2022",
            "endDate": "01-Apr-2031",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "7.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2022",
                "endDate": "16-Dec-2027",
                "successPercentage": "62%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2027",
                "endDate": "23-Apr-2030",
                "successPercentage": "30%",
                "predictedDateL50": "04-Jun-2027",
                "predictedDateU50": "27-Mar-2028",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Apr-2030",
                "endDate": "21-Feb-2031",
                "successPercentage": "79%",
                "predictedDateL50": "18-Apr-2029",
                "predictedDateU50": "13-Sep-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Feb-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Nov-2030",
                "predictedDateU50": "01-Apr-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "31-Dec-2027",
                "notes": "In October 2022, phase I/II trial (NCT05200559) of E-7777 in combination with pembrolizumab in metastatic solid tumor patients was expected to complete in December 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2022",
            "endDate": "20-Aug-2031",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "38%",
            "timeToRegistration": "7.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2022",
                "endDate": "16-Dec-2027",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2027",
                "endDate": "22-Aug-2030",
                "successPercentage": "64%",
                "predictedDateL50": "30-Apr-2027",
                "predictedDateU50": "26-Apr-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Aug-2030",
                "endDate": "10-Jul-2031",
                "successPercentage": "92%",
                "predictedDateL50": "02-Jul-2029",
                "predictedDateU50": "23-Jan-2031",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Jul-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Mar-2031",
                "predictedDateU50": "20-Aug-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "31-Dec-2027",
                "notes": "In October 2022, phase I/II trial (NCT05200559) of E-7777 in combination with pembrolizumab in metastatic solid tumor patients was expected to complete in December 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2022",
            "endDate": "15-Aug-2031",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "7.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2022",
                "endDate": "16-Dec-2027",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2027",
                "endDate": "16-Aug-2030",
                "successPercentage": "62%",
                "predictedDateL50": "30-Apr-2027",
                "predictedDateU50": "26-Apr-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Aug-2030",
                "endDate": "04-Jul-2031",
                "successPercentage": "91%",
                "predictedDateL50": "28-Jun-2029",
                "predictedDateU50": "17-Jan-2031",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Jul-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Mar-2031",
                "predictedDateU50": "15-Aug-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "31-Dec-2027",
                "notes": "In October 2022, phase I/II trial (NCT05200559) of E-7777 in combination with pembrolizumab in metastatic solid tumor patients was expected to complete in December 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "29387",
              "name": "Dr Reddy's Laboratories Ltd"
            },
            "indication": {
              "id": "4250",
              "name": "Metastatic renal cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2022",
            "endDate": "03-Jul-2031",
            "statusDate": "30-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "7.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2022",
                "endDate": "16-Dec-2027",
                "successPercentage": "65%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Dec-2027",
                "endDate": "08-Jul-2030",
                "successPercentage": "53%",
                "predictedDateL50": "16-May-2027",
                "predictedDateU50": "31-Mar-2028",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jul-2030",
                "endDate": "21-May-2031",
                "successPercentage": "79%",
                "predictedDateL50": "29-May-2029",
                "predictedDateU50": "21-Nov-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2031",
                "predictedDateU50": "03-Jul-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2027",
                "milestoneExtendedDate": "31-Dec-2027",
                "notes": "In October 2022, phase I/II trial (NCT05200559) of E-7777 in combination with pembrolizumab in metastatic solid tumor patients was expected to complete in December 2027 [ <ulink linkID=\"2607116\" linkType=\"Reference\">  2607116 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "7871",
        "displayName": "pirfenidone",
        "drugPrograms": [
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "55",
              "name": "Cardiac failure"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Mar-2017",
            "endDate": "",
            "statusDate": "07-Mar-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Mar-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "291",
              "name": "Rheumatoid arthritis"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2022",
            "endDate": "07-Sep-2028",
            "statusDate": "05-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2022",
                "endDate": "27-Dec-2024",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Dec-2024",
                "endDate": "20-Jul-2027",
                "successPercentage": "19%",
                "predictedDateL50": "11-Apr-2024",
                "predictedDateU50": "27-Apr-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2027",
                "endDate": "19-Jul-2028",
                "successPercentage": "64%",
                "predictedDateL50": "10-Jun-2026",
                "predictedDateU50": "03-Dec-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2028",
                "predictedDateU50": "07-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "291",
              "name": "Rheumatoid arthritis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Sep-2022",
            "endDate": "09-Jul-2028",
            "statusDate": "05-Sep-2022",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Sep-2022",
                "endDate": "27-Dec-2024",
                "successPercentage": "5%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Dec-2024",
                "endDate": "20-Jul-2027",
                "successPercentage": "18%",
                "predictedDateL50": "11-Apr-2024",
                "predictedDateU50": "27-Apr-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "20-Jul-2027",
                "endDate": "29-May-2028",
                "successPercentage": "66%",
                "predictedDateL50": "10-Jun-2026",
                "predictedDateU50": "03-Dec-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Feb-2028",
                "predictedDateU50": "09-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2466",
              "name": "Interstitial lung disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy, Priority Review",
            "startDate": "31-Oct-2013",
            "endDate": "",
            "statusDate": "21-Jan-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Oct-2013",
                "endDate": "21-Jan-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Jan-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2466",
              "name": "Interstitial lung disease"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-May-2017",
            "endDate": "",
            "statusDate": "15-May-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-May-2017",
                "endDate": "04-Feb-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Feb-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2985",
              "name": "Lung transplantation"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2018",
            "endDate": "30-Jul-2028",
            "statusDate": "27-Apr-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "7%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2018",
                "endDate": "16-Nov-2024",
                "successPercentage": "30%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Nov-2024",
                "endDate": "08-Aug-2027",
                "successPercentage": "26%",
                "predictedDateL50": "08-Mar-2024",
                "predictedDateU50": "05-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Aug-2027",
                "endDate": "20-Jun-2028",
                "successPercentage": "89%",
                "predictedDateL50": "13-Jun-2026",
                "predictedDateU50": "13-Jan-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Mar-2028",
                "predictedDateU50": "30-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "12847",
              "name": "Scleroderma-associated interstitial lung disease"
            },
            "country": {
              "id": "EU",
              "name": "EU (IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "31-Aug-2013",
            "endDate": "",
            "statusDate": "29-Sep-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "12847",
              "name": "Scleroderma-associated interstitial lung disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Aug-2013",
            "endDate": "",
            "statusDate": "29-Sep-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Aug-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "51160",
        "displayName": "nintedanib",
        "drugPrograms": [
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "1128",
              "name": "Neuroendocrine tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-May-2015",
            "endDate": "",
            "statusDate": "18-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2014",
            "endDate": "",
            "statusDate": "31-May-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-May-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Nov-2018",
            "endDate": "",
            "statusDate": "14-Nov-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "14-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "2466",
              "name": "Interstitial lung disease"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2011",
            "endDate": "01-Nov-2024",
            "statusDate": "17-Jan-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-May-2011",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "29-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "28-Jun-2023",
                "predictedDateU50": "12-Feb-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Jun-2024",
                "predictedDateU50": "01-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In April 2019, clinical results from phase III trial for progressive fibrosing interstitial lung disease (PF-ILD) was expected in later that year [<ulink linkType=\"Reference\" linkID=\"2142885\">2142885</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "09-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, phase III study (NCT02999178; INBUILD) results were reported. The study met its primary endpoint and demonstrated the efficacy and safety of nintedanib in patients with a broad range of progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis [<ulink linkType=\"Reference\" linkID=\"2202522\">2202522</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, phase III study (NCT02999178; INBUILD) results were reported. The study met its primary endpoint and demonstrated the efficacy and safety of nintedanib in patients with a broad range of progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis [<ulink linkType=\"Reference\" linkID=\"2202522\">2202522</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, topline data from the phase III trial (NCT02999178; INBUILD) in patients with interstitial lung diseases were published. Among nintedanib and placebo groups, the difference in the annual rate of decline in FVC in  patients with a UIP-like fibrotic pattern on HRCT versus other fibrotic patterns on HRCT was 127.8 versus 75.4 ml/year (p = 0.23) [<ulink linkType=\"Reference\" linkID=\"2304487\">2304487</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "05-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, positive data were reported for phase III trial (NCT02999178; INBUILD) in patients with interstitial lung diseases which showed that the primary endpoint was met. Among nintedanib and placebo groups, the difference in the annual rate of decline in FVC in  patients with a UIP-like fibrotic pattern on HRCT versus other fibrotic patterns on HRCT was 127.8 versus 75.4 ml/year (p = 0.23) [<ulink linkType=\"Reference\" linkID=\"2304487\">2304487</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "2466",
              "name": "Interstitial lung disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "30-Apr-2011",
            "endDate": "17-Apr-2024",
            "statusDate": "25-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Apr-2011",
                "endDate": "25-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "12.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jul-2023",
                "endDate": "18-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "17-Apr-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "09-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, phase III study (NCT02999178; INBUILD) results were reported. The study met its primary endpoint and demonstrated the efficacy and safety of nintedanib in patients with a broad range of progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis [<ulink linkType=\"Reference\" linkID=\"2202522\">2202522</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "09-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, phase III study (NCT02999178; INBUILD) results were reported. The study met its primary endpoint and demonstrated the efficacy and safety of nintedanib in patients with a broad range of progressive fibrosing interstitial lung diseases other than idiopathic pulmonary fibrosis [<ulink linkType=\"Reference\" linkID=\"2202522\">2202522</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "10-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, nintedanib received Breakthrough Therapy designation from the US FDA for the treatment of chronic fibrosing interstitial lung diseases [<ulink linkType=\"Reference\" linkID=\"2202746\">2202746</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Positive Outcome",
                "milestoneDate": "09-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, the US FDA approved nintedanib for the treatment of chronic fibrosing interstitial lung diseases with a progressive phenotype [ <ulink linkID=\"2253160\" linkType=\"Reference\">  2253160 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "05-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, positive data were reported for phase III trial (NCT02999178; INBUILD) in patients with interstitial lung diseases which showed that the primary endpoint was met. Among nintedanib and placebo groups, the difference in the annual rate of decline in FVC in  patients with a UIP-like fibrotic pattern on HRCT versus other fibrotic patterns on HRCT was 127.8 versus 75.4 ml/year (p = 0.23) [<ulink linkType=\"Reference\" linkID=\"2304487\">2304487</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, topline data from the phase III trial (NCT02999178; INBUILD) in patients with interstitial lung diseases were published. Among nintedanib and placebo groups, the difference in the annual rate of decline in FVC in  patients with a UIP-like fibrotic pattern on HRCT versus other fibrotic patterns on HRCT was 127.8 versus 75.4 ml/year (p = 0.23) [<ulink linkType=\"Reference\" linkID=\"2304487\">2304487</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In November 2020, the phase IV ENDCOV-I trial (NCT04619680) to assess the effect of nintedanib in lowering lung fibrosis in patients who have acute lung injury/ILD secondary to COVID-19  was expected to complete in July 2021[<ulink linkType=\"Reference\" linkID=\"2372217\">2372217</ulink>], [<ulink linkType=\"Reference\" linkID=\"2364630\">2364630</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "25-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, a phase III trial (NCT04093024; 1199-0337; 2018-004530-14) in children and adolescents with fibrosing ILD was expected to complete in February 2022 [<ulink linkType=\"Reference\" linkID=\"2309118\">2309118</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "24-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial (NCT04093024) in progressive ILD was completed [ <ulink linkID=\"3023990\" linkType=\"Reference\"> 3023990 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "25-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the US FDA accepted the sNDA of nintedanib for the potential treatment for children and adolescent patients with fibrosing ILD and aged between 6 to 17 years old [ <ulink linkID=\"3023990\" linkType=\"Reference\"> 3023990 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2015",
            "endDate": "",
            "statusDate": "03-May-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-May-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14881",
              "name": "Boehringer Ingelheim International GmbH"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Jul-2017",
            "endDate": "27-Jul-2028",
            "statusDate": "07-Jul-2017",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "6%",
            "timeToRegistration": "4.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Jul-2017",
                "endDate": "10-Nov-2024",
                "successPercentage": "25%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Nov-2024",
                "endDate": "12-Jul-2027",
                "successPercentage": "28%",
                "predictedDateL50": "12-Feb-2024",
                "predictedDateU50": "03-Jun-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2027",
                "endDate": "16-Jun-2028",
                "successPercentage": "85%",
                "predictedDateL50": "24-May-2026",
                "predictedDateU50": "13-Dec-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Jun-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Feb-2028",
                "predictedDateU50": "27-Jul-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "52798",
        "displayName": "lebrikizumab",
        "drugPrograms": [
          {
            "company": {
              "id": "1065735",
              "name": "Dermira Inc"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "17810",
              "name": "Eli Lilly & Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "10-Mar-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1065735",
              "name": "Dermira Inc"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "17810",
              "name": "Eli Lilly & Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "08-Oct-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1065735",
              "name": "Dermira Inc"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": "17810",
              "name": "Eli Lilly & Co"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "08-Nov-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1065735",
              "name": "Dermira Inc"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track",
            "startDate": "11-May-2015",
            "endDate": "03-Jun-2024",
            "statusDate": "01-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-May-2015",
                "endDate": "24-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2019",
                "endDate": "01-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Nov-2022",
                "endDate": "06-Apr-2024",
                "successPercentage": "24%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jan-2024",
                "predictedDateU50": "03-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2019",
                "milestoneExtendedDate": "31-Mar-2019",
                "notes": "In February 2019, top-line data from the phase IIb trial (NCT03443024) were expected in the second half of March 2019 [<ulink linkType=\"Reference\" linkID=\"2123595\">2123595</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, positive topline data from a phase IIb dose-ranging study of atopic dermatitis were reported [<ulink linkType=\"Reference\" linkID=\"2130887\">2130887</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2019, positive topline data from a phase IIb dose-ranging study of atopic dermatitis were reported [<ulink linkType=\"Reference\" linkID=\"2130887\">2130887</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2019",
                "milestoneExtendedDate": "30-Apr-2019",
                "notes": "In October 2018, topline results from the phase IIb trial (NCT03443024) were expected by early April 2019 [<ulink linkType=\"Reference\" linkID=\"2086392\">2086392</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "10-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, the FDA granted Fast Track designation for the treatment of moderate-to-severe atopic dermatitis [<ulink linkType=\"Reference\" linkID=\"2227146\">2227146</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In October 2019, top-line data from the phase III ADvocate1 trial (NCT04146363) in patients with atopic dermatitis was expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2202761\">2202761</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2021, top-line data from the phase III (NCT04146363; ADvocate1)in patients with atopic dermatitis were expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2411458\">2411458</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2019, the phase III trial (NCT04178967) was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2222184\">2222184</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "01-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, regulatory filing was submitted in the US for the treatment of moderate to severe atopic dermatitis [ <ulink linkID=\"2762043\" linkType=\"Reference\"> 2762043 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the US FDA issued a complete response letter (CRL) to the BLA, based on findings which appeared during the inspection of manufacturing site [ <ulink linkID=\"3305512\" linkType=\"Reference\"> 3305512 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive data from the phase III trial (NCT04392154) in atopic dermatitis demonstrating efficacy of 76%, 96%, 83% and 90% in monthly (Q4W) dosing and 86%, 96%, 82% and 100% in biweekly (Q2W) dosing in IGA score, EASI 75 score, EASI 90 score and Pruritus NRS (Itch) &gt;/= 4-point improvement​ score, respectively for patients who joined the trial from ADvocate I and II trial and 79%, 96%, 72% and 90% in monthly (Q4W) dosing and 84%, 95%, 85% and 82% in biweekly (Q2W) dosing in IGA score, EASI 75 score, EASI 90 score and Pruritus NRS (Itch) &gt;/= 4-point improvement​ score, respectively for patients who joined the trial from ADhere trial were reported [ <ulink linkID=\"3475309\" linkType=\"Reference\"> 3475309 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "22-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, data from the phase III trial (NCT04392154) in atopic dermatitis were expected later that month [ <ulink linkID=\"3475309\" linkType=\"Reference\"> 3475309 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "15-Mar-2024",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, a phase III trial (NCT05369403) in atopic dermatitis was expected to complete in March 2024 [ <ulink linkID=\"2680936\" linkType=\"Reference\"> 2680936 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14061",
              "name": "Almirall SA"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Sep-2017",
            "endDate": "17-Nov-2023",
            "statusDate": "13-Oct-2023",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Sep-2017",
                "endDate": "24-Sep-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2019",
                "endDate": "28-Oct-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Oct-2022",
                "endDate": "17-Nov-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Nov-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In October 2019, top-line data from the phase III ADvocate1 trial (NCT04146363) in patients with atopic dermatitis was expected in the first half of 2021 [<ulink linkType=\"Reference\" linkID=\"2202761\">2202761</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In February 2021, top-line data from the phase III (NCT04146363; ADvocate1)in patients with atopic dermatitis were expected in the second half of 2021 [<ulink linkType=\"Reference\" linkID=\"2411458\">2411458</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, 16-week, positive topline data were reported from the phase III (NCT04146363; ADvocate1) in patients with atopic dermatitis, showing at least 75% of skin clearance in more than half of people. Additional improvements with sleep disturbance and quality of life were also observed [ <ulink linkID=\"2512131\" linkType=\"Reference\">  2512131 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, a phase III trial (NCT04250337) in atopic dermatitis was completed [ <ulink linkID=\"3202346\" linkType=\"Reference\"> 3202346 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2019, the phase III trial (NCT04178967) was expected to complete in December 2021 [<ulink linkType=\"Reference\" linkID=\"2222184\">2222184</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In December 2021, a phase III trial (NCT05149313)  for moderate-to-severe atopic dermatitis was planned to begin later that month in France [  <ulink linkID=\"2595795\" linkType=\"Reference\">  2595795 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "03-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial (NCT04146363) in atopic dermatitis was completed [ <ulink linkID=\"2227331\" linkType=\"Reference\"> 2227331 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive one-year data were reported from ADvocate1 (NCT04146363) and ADvocate2 (NCT04178967). In ADvocate1, EASI-75 was maintained at one-year by 79% of patients receiving lebrikizumab q4w or q2w. In ADvocate2, EASI-75 was maintained at one-year by 85% of patients receiving lebrikizumab q4w, and by 77% of patients receiving lebrikizumab q2w [  <ulink linkID=\"2681995\" linkType=\"Reference\">  2681995 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In June 2022, following the report of positive one-year data from ADvocate 1 and ADvocate 2, an EU filing was expected in 2H22 [  <ulink linkID=\"2681995\" linkType=\"Reference\">  2681995 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "28-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, the EMA accepted an MAA for the treatment of moderate to severe atopic dermatitis based on data from the phase III ADvocate 1, ADvocate 2 and ADhere studies.  At that time, approval was expected in 2H23 [ <ulink linkID=\"2760444\" linkType=\"Reference\">  2760444 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In November 2022, EU approval for atopic dermatitis was expected in late 2023 [ <ulink linkID=\"2769205\" linkType=\"Reference\"> 2769205 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2020, expected launch for atopic dermatitis in the EU was in 2023 [ <ulink linkID=\"2265229\" linkType=\"Reference\">  2265229 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive results from the phase III trial (NCT04178967) and (NCT04146363) in atopic dermatitis were published [ <ulink linkID=\"3002244\" linkType=\"Reference\"> 3002244 </ulink>], [ <ulink linkID=\"2880016\" linkType=\"Reference\"> 2880016 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, positive clinical data from the phase III trial (NCT04146363) and (NCT04178967) in atopic dermatitis demonstrating significant (p&lt;0.001) EASI-75 response in 52.1% patients compared with 18.1% in placebo group, and significant EASI-75 response (p&lt;0.001) in 58.8% patients as compared to 16.2% in placebo group, respectively were published [ <ulink linkID=\"3201761\" linkType=\"Reference\"> 3201761 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, endpoints from the phase III trial (NCT04146363) and (NCT04178967) in atopic dermatitis were met [ <ulink linkID=\"3201761\" linkType=\"Reference\"> 3201761 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "28-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, a phase IIII trial (NCT04178967) in atopic dermatitis was completed [ <ulink linkID=\"2222184\" linkType=\"Reference\"> 2222184 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In October 2022, the EMA accepted an MAA for the treatment of moderate to severe atopic dermatitis based on data from the phase III ADvocate 1, ADvocate 2 and ADhere studies. At that time, approval was expected in 2H23 [ <ulink linkID=\"2760444\" linkType=\"Reference\"> 2760444 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, CHMP issued a positive opinion recommending the marketing authorization of lebrikizumab for the treatment of adult and adolescent patients aged 12 years and older with a body weight of at least 40 kg with moderate-to-severe atopic dermatitis and are candidates for systemic therapy, based oh the phase III trials (ADvocate 1, ADvocate 2 and Adhere) [ <ulink linkID=\"3196776\" linkType=\"Reference\"> 3196776 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, the drug approval was expected in Q423 [ <ulink linkID=\"2826679\" linkType=\"Reference\">  2826679 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In February 2023, the drug approval was expected in Q423 [ <ulink linkID=\"2826679\" linkType=\"Reference\">  2826679 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In May 2022, the drug launch was expected in late 2023 [ <ulink linkID=\"2665322\" linkType=\"Reference\">  2665322 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, positive data from the phase III trial (NCT04392154) in atopic dermatitis demonstrating efficacy of 76%, 96%, 83% and 90% in monthly (Q4W) dosing and 86%, 96%, 82% and 100% in biweekly (Q2W) dosing in IGA score, EASI 75 score, EASI 90 score and Pruritus NRS (Itch) &gt;/= 4-point improvement​ score, respectively for patients who joined the trial from ADvocate I and II trial and 79%, 96%, 72% and 90% in monthly (Q4W) dosing and 84%, 95%, 85% and 82% in biweekly (Q2W) dosing in IGA score, EASI 75 score, EASI 90 score and Pruritus NRS (Itch) &gt;/= 4-point improvement​ score, respectively for patients who joined the trial from ADhere trial were reported [ <ulink linkID=\"3475309\" linkType=\"Reference\"> 3475309 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "22-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, data from the phase III trial (NCT04392154) in atopic dermatitis were expected later that month [ <ulink linkID=\"3475309\" linkType=\"Reference\"> 3475309 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "23-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, regulatory decisions for lebrikizumab in moderate-to-severe AD in additional European markets, including the UK and Switzerland were expected in 2024 [ <ulink linkID=\"3429098\" linkType=\"Reference\"> 3429098 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "23-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, new primary data from phase III trial (NCT05149313; ADvantage) of lebrikizumab in combination with topical corticosteroids in adult and adolescent patients with moderate-to-severe atopic dermatitis who are not adequately controlled with cyclosporine or for whom cyclosporine is not medically advisable were presented [ <ulink linkID=\"3429098\" linkType=\"Reference\"> 3429098 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "54452",
        "displayName": "rivoceranib",
        "drugPrograms": [
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2010",
            "endDate": "",
            "statusDate": "30-Jun-2010",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2010",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Nov-2017",
            "endDate": "",
            "statusDate": "29-Nov-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Nov-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Feb-2016",
            "endDate": "02-Sep-2027",
            "statusDate": "11-Feb-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Feb-2016",
                "endDate": "21-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2024",
                "endDate": "04-Jun-2026",
                "successPercentage": "95%",
                "predictedDateL50": "08-Oct-2023",
                "predictedDateU50": "13-Apr-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Jun-2026",
                "endDate": "06-Jul-2027",
                "successPercentage": "87%",
                "predictedDateL50": "26-May-2025",
                "predictedDateU50": "23-Oct-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Feb-2027",
                "predictedDateU50": "02-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from a phase II study (NCT03736863) of camrelizumab plus apatinib as second-line treatment in 33 patients with unresectable locally advanced, locally recurrent, or metastatic esophageal squamous cell carcinoma  were presented. Among the 17 evaluable patients, the objective response rate (primary endpoint) was 41%; seven had the best overall response of partial response; nine patients had stable disease. A proportion of 67% of patients had treatment-related adverse events (TRAEs), with 36% with grade &gt;/= 3. The most commonly reported TRAEs included decreased WBC count (33%), hypokalaemia (27%), and increased ALT (24%) [ <ulink linkID=\"2823805\" linkType=\"Reference\">  2823805 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "311",
              "name": "T-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Oct-2018",
            "endDate": "23-Sep-2027",
            "statusDate": "20-Oct-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Oct-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "19-May-2026",
                "successPercentage": "95%",
                "predictedDateL50": "28-May-2023",
                "predictedDateU50": "12-May-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-May-2026",
                "endDate": "15-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "29-Apr-2025",
                "predictedDateU50": "09-Oct-2026",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2027",
                "predictedDateU50": "23-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "18-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, primary endpoint (objective response rate) of a phase II trial (NCT03701022) of camrelizumab in combination with apatinib, in patients with relapsed or refractory peripheral T-cell lymphoma was met. Among 11 efficacy evaluable patients, objective response rate was 36.4% and included complete response in one patient and partial response in three patients. Grade 4 or higher AEs were not reported [<ulink linkType=\"Reference\" linkID=\"2325088\">2325088</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "18-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, interim data of a phase II trial (NCT03701022) of camrelizumab in combination with apatinib, in 15 patients with relapsed or refractory peripheral T-cell lymphoma were presented. Among 11 efficacy evaluable patients, objective response rate was 36.4% and included complete response in one patient and partial response in three patients. Grade 4 or higher AEs were not reported [<ulink linkType=\"Reference\" linkID=\"2325088\">2325088</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "427",
              "name": "Uterine cervix tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Feb-2020",
            "endDate": "21-Aug-2027",
            "statusDate": "12-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "78%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Feb-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "27-Mar-2026",
                "successPercentage": "94%",
                "predictedDateL50": "27-Jul-2023",
                "predictedDateU50": "15-Mar-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Mar-2026",
                "endDate": "02-Jun-2027",
                "successPercentage": "87%",
                "predictedDateL50": "26-Mar-2025",
                "predictedDateU50": "09-Aug-2026",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Jan-2027",
                "predictedDateU50": "21-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, topline data of a phase II trial (NCT03816553) in patients with metastatic, persistent, or recurrent cervical cancer were presented which showed that the primary endpoint (objective response rate; ORR) was met. The ORR was 55.6% [<ulink linkType=\"Reference\" linkID=\"2283675\">2283675</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoint (objective response rate; ORR) of a phase II trial (NCT03816553) in patients with metastatic, persistent, or recurrent cervical cancer was met. The ORR was 55.6% [<ulink linkType=\"Reference\" linkID=\"2283675\">2283675</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In January 2020, it was reported that a phase II trial (NCT03816553) in patients with metastatic, persistent, or recurrent cervical cancer was expected to complete in June 19, 2021 [<ulink linkType=\"Reference\" linkID=\"2290213\">2290213</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase II trial of SHR-1210 in combined with apatinib in subjects with relapsed or refractory uterine /cervical and ovarian carcinoma was expected to complete in Febraury 2023 [<ulink linkType=\"Reference\" linkID=\"2247395\">2247395</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "623",
              "name": "Head and neck tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "05-Jul-2017",
            "endDate": "",
            "statusDate": "05-Jul-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "05-Jul-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "740",
              "name": "Uterus tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Feb-2020",
            "endDate": "05-Apr-2028",
            "statusDate": "12-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Feb-2020",
                "endDate": "22-Jun-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "22-Jun-2024",
                "endDate": "30-Nov-2026",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "10-Oct-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2026",
                "endDate": "26-Jan-2028",
                "successPercentage": "95%",
                "predictedDateL50": "10-Nov-2025",
                "predictedDateU50": "22-Apr-2027",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Sep-2027",
                "predictedDateU50": "05-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase II trial of SHR-1210 in combined with apatinib in subjects with relapsed or refractory uterine /cervical and ovarian carcinoma was expected to complete in Febraury 2023 [<ulink linkType=\"Reference\" linkID=\"2247395\">2247395</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1134",
              "name": "Thyroid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Dec-2016",
            "endDate": "",
            "statusDate": "01-Dec-2016",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "01-Dec-2016",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Apr-2018",
            "endDate": "",
            "statusDate": "20-Apr-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "20-Apr-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1516",
              "name": "Biliary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Feb-2017",
            "endDate": "",
            "statusDate": "17-Feb-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "17-Feb-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "07-Feb-2018",
            "endDate": "",
            "statusDate": "07-Feb-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "07-Feb-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1768",
              "name": "Nasopharyngeal carcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Apr-2017",
            "endDate": "",
            "statusDate": "01-Apr-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Apr-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "1772",
              "name": "Osteosarcoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Jan-2018",
            "endDate": "",
            "statusDate": "01-Jan-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Jan-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3257",
              "name": "Stage IV melanoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2020",
            "endDate": "25-Dec-2027",
            "statusDate": "31-May-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-May-2020",
                "endDate": "14-May-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-May-2024",
                "endDate": "26-Sep-2026",
                "successPercentage": "95%",
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "14-Aug-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Sep-2026",
                "endDate": "28-Oct-2027",
                "successPercentage": "87%",
                "predictedDateL50": "17-Sep-2025",
                "predictedDateU50": "14-Feb-2027",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Jun-2027",
                "predictedDateU50": "25-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3378",
              "name": "Soft tissue sarcoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Nov-2018",
            "endDate": "",
            "statusDate": "29-Nov-2018",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Nov-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Apr-2011",
            "endDate": "",
            "statusDate": "10-Feb-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Apr-2011",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2010",
            "endDate": "",
            "statusDate": "01-Nov-2010",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Mar-2010",
                "endDate": "31-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Feb-2016",
            "endDate": "12-Apr-2028",
            "statusDate": "11-Feb-2016",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "59%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Feb-2016",
                "endDate": "21-Jan-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2024",
                "endDate": "27-Sep-2026",
                "successPercentage": "68%",
                "predictedDateL50": "25-May-2023",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Sep-2026",
                "endDate": "27-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Aug-2025",
                "predictedDateU50": "03-Mar-2027",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jul-2027",
                "predictedDateU50": "12-Apr-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive data from a phase II study (NCT03736863) of camrelizumab plus apatinib as second-line treatment in 33 patients with unresectable locally advanced, locally recurrent, or metastatic esophageal squamous cell carcinoma  were presented. Among the 17 evaluable patients, the objective response rate (primary endpoint) was 41%; seven had the best overall response of partial response; nine patients had stable disease. A proportion of 67% of patients had treatment-related adverse events (TRAEs), with 36% with grade &gt;/= 3. The most commonly reported TRAEs included decreased WBC count (33%), hypokalaemia (27%), and increased ALT (24%) [ <ulink linkID=\"2823805\" linkType=\"Reference\">  2823805 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Sep-2020",
            "endDate": "26-Jul-2027",
            "statusDate": "30-Sep-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "30-Sep-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "27-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "22-Aug-2023",
                "predictedDateU50": "05-Mar-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Apr-2026",
                "endDate": "28-May-2027",
                "successPercentage": "88%",
                "predictedDateL50": "16-Apr-2025",
                "predictedDateU50": "15-Sep-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Jan-2027",
                "predictedDateU50": "26-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, data from a phase II study (NCT04569916) of radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib in 55 patients with advanced solid tumor were presented. All grade and grade 3 to 4 TRAEs were reported in 98.2 and 45.5% of patients, respectively. Among 42 efficacy evaluable patients, at a median follow-up of 41 weeks, ORR was 35.7%; DCR was 97.6%; the number of patients with PR, SD, and PD was 15, 26, and 1, respectively [ <ulink linkID=\"2692160\" linkType=\"Reference\">  2692160 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2023",
                "milestoneExtendedDate": "31-May-2023",
                "notes": "In September 2020, a phase II study (NCT04569916; IIT-RT-IRI-SHR1210-APA) of radiotherapy combined with irinotecan liposome and apatinib followed by PD-1 antibody and apatinib was expected to be completed in May 2023 [ <ulink linkID=\"2722685\" linkType=\"Reference\">  2722685 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1006925",
              "name": "Jiangsu Hengrui Medicine Co Ltd"
            },
            "indication": {
              "id": "3866",
              "name": "Metastatic ovary cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Aug-2017",
            "endDate": "14-Nov-2025",
            "statusDate": "16-Aug-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "01-Aug-2017",
                "endDate": "16-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Aug-2019",
                "endDate": "26-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "26-Jun-2024",
                "endDate": "29-Aug-2025",
                "successPercentage": "94%",
                "predictedDateL50": "14-Jan-2024",
                "predictedDateU50": "22-Oct-2024",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Apr-2025",
                "predictedDateU50": "14-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "20-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, a clinical trial application was filed in China [<ulink linkType=\"Reference\" linkID=\"2179199\">2179199</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "21-Oct-2019",
                "milestoneExtendedDate": "",
                "notes": "In October 2019, an implied clinical trial approval of the drug was granted for recurrent ovarian cancer in China [<ulink linkType=\"Reference\" linkID=\"2201752\">2201752</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "03-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, an IND was filed in China [<ulink linkType=\"Reference\" linkID=\"2222756\">2222756</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "10-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, an implied trial approval was granted for fluazolepali in combination with apatinib as the maintenance therapy of  advanced epithelial ovarian cancer,   fallopian tube cancer and primary peritoneal carcinoma [<ulink linkType=\"Reference\" linkID=\"2241125\">2241125</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "25-Feb-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase III trial was expected to start in February 2020 in China [<ulink linkType=\"Reference\" linkID=\"2253382\">2253382</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2020",
                "milestoneExtendedDate": "31-May-2020",
                "notes": "In May 2020, a phase II trial was expected to start in May2020 in China [<ulink linkType=\"Reference\" linkID=\"2285862\">2285862</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "29-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, an IND was filed in China [<ulink linkType=\"Reference\" linkID=\"2274354\">2274354</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "23-Jul-2020",
                "milestoneExtendedDate": "",
                "notes": "In July 2020, an implied clinical trial approval of the drug was obtained for advanced ovarian cancer in combination with fluazolepali in China [<ulink linkType=\"Reference\" linkID=\"2294364\">2294364</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In May 2020, a phase II trial was expected to complete in June 2021 in China [<ulink linkType=\"Reference\" linkID=\"2285862\">2285862</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, a phase II trial (NCT04517357) for fluzoparib combined with apatinib in relapsed ovarian cancer patients was expected to complete in March 2022 [<ulink linkType=\"Reference\" linkID=\"2320587\">2320587</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase II trial of SHR-1210 in combined with apatinib in subjects with relapsed or refractory uterine /cervical and ovarian carcinoma was expected to complete in Febraury 2023 [<ulink linkType=\"Reference\" linkID=\"2247395\">2247395</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "25-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a phase III trial </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Dec-2017",
            "endDate": "",
            "statusDate": "22-Dec-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "22-Dec-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2012",
            "endDate": "",
            "statusDate": "27-Apr-2012",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Apr-2012",
            "endDate": "",
            "statusDate": "27-Apr-2012",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "27-Apr-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Jun-2019",
            "endDate": "17-Jun-2025",
            "statusDate": "10-Jun-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "88%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Jun-2019",
                "endDate": "30-Jun-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Jun-2024",
                "endDate": "02-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jan-2024",
                "predictedDateU50": "27-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jan-2025",
                "predictedDateU50": "17-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive data from study phase III trial (NCT03764293; CARES-310) for the treatment of unresectable hepatocellular carcinoma were published [ <ulink linkID=\"3023534\" linkType=\"Reference\"> 3023534 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "30-Jun-2019",
            "endDate": "01-Jun-2024",
            "statusDate": "17-May-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "94%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2019",
                "endDate": "17-May-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-May-2023",
                "endDate": "02-May-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2024",
                "predictedDateU50": "01-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, a phase III trial for advanced HCC was expected to complete in January 2022 [<ulink linkType=\"Reference\" linkID=\"2110647\">2110647</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "11-Nov-2021",
                "milestoneExtendedDate": "",
                "notes": "In November 2021, the US FDA granted Orphan Drug designation for rivoceranib for the treatment of hepatocellular carcinoma (HCC) [ <ulink linkID=\"2565475\" linkType=\"Reference\">  2565475 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "17-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, an NDA was submitted to the US FDA for combination of rivoceranib and camrelizumab as first-line treatment option for unresectable hepatocellular carcinoma [ <ulink linkID=\"2941359\" linkType=\"Reference\"> 2941359 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive data from study phase III trial (NCT03764293; CARES-310) for the treatment of unresectable hepatocellular carcinoma were published [ <ulink linkID=\"3023534\" linkType=\"Reference\"> 3023534 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "16-May-2024",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the US FDA accepted the NDA application, with a PDUFA date of May 16, 2024 [ <ulink linkID=\"3014030\" linkType=\"Reference\"> 3014030 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Jun-2019",
            "endDate": "15-Oct-2025",
            "statusDate": "30-Jun-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "30-Jun-2019",
                "endDate": "23-Jul-2024",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Jul-2024",
                "endDate": "20-Aug-2025",
                "successPercentage": "93%",
                "predictedDateL50": "26-Nov-2023",
                "predictedDateU50": "27-Oct-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Aug-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Apr-2025",
                "predictedDateU50": "15-Oct-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Jan-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2018, a phase III trial for advanced HCC was expected to complete in January 2022 [<ulink linkType=\"Reference\" linkID=\"2110647\">2110647</ulink>]</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "24-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive data from study phase III trial (NCT03764293; CARES-310) for the treatment of unresectable hepatocellular carcinoma were published [ <ulink linkID=\"3023534\" linkType=\"Reference\"> 3023534 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Jun-2018",
            "endDate": "09-Aug-2028",
            "statusDate": "19-Jun-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "4.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Jun-2018",
                "endDate": "24-Dec-2024",
                "successPercentage": "48%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Dec-2024",
                "endDate": "08-Sep-2027",
                "successPercentage": "62%",
                "predictedDateL50": "05-Mar-2024",
                "predictedDateU50": "19-Jul-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Sep-2027",
                "endDate": "06-Jul-2028",
                "successPercentage": "90%",
                "predictedDateL50": "21-Jul-2026",
                "predictedDateU50": "16-Feb-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jul-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Mar-2028",
                "predictedDateU50": "09-Aug-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2016",
            "endDate": "06-Nov-2024",
            "statusDate": "24-Feb-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2016",
                "endDate": "14-Mar-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Mar-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "04-Oct-2024",
                "successPercentage": "94%",
                "predictedDateL50": "11-May-2023",
                "predictedDateU50": "28-Feb-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Jun-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In November 2022, HLB planned to apply for a conditional approval for rivoceranib to treat adenocarcinoma to the Ministry of Food and Drug Safety Ministry in the first quarter of 2023. At that time, drug was designated as a rare drug by ministry for the treatment of metastatic or recurrent adenocarcinoma [ <ulink linkID=\"2767196\" linkType=\"Reference\">  2767196 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3153",
              "name": "Adenoid tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Mar-2020",
            "endDate": "12-Apr-2027",
            "statusDate": "01-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "70%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Mar-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "23-Apr-2026",
                "successPercentage": "78%",
                "predictedDateL50": "10-Jan-2023",
                "predictedDateU50": "29-Aug-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Apr-2026",
                "endDate": "26-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "17-Apr-2025",
                "predictedDateU50": "13-Sep-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Nov-2026",
                "predictedDateU50": "12-Apr-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) from the phase II trial (NCT04119453) in 80 patients with patients with recurrent or metastatic adenoid cystic carcinoma were met. Across total patients, VEGFR-naïve and VEGFR-treated patients (n = 73, 60 and 13), objective response rates (ORR) (primary endpoint) and partial response (PR) rates were 15.1, 18.3 and 0% each (assessed by investigator) and 9.6, 8.3 and 15.4% each (assessed by blinded independent review committee, BIRC), respectively [ <ulink linkID=\"2692145\" linkType=\"Reference\">  2692145 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, top-line data of a phase II trial (NCT04119453) in 80 patients with patients with recurrent or metastatic adenoid cystic carcinoma were presented. Across total patients, VEGFR-naïve and VEGFR-treated patients (n = 73, 60 and 13), ORR and PR rates were 15.1, 18.3 and 0% each (assessed by investigator) and 9.6, 8.3 and 15.4% each (assessed by blinded independent review committee, BIRC), DCR were 64.4, 61.7 and 76.9% (investigator) and 65.8, 65.0 and 69.2% (BIRC), median PFS was 9.0, 9.0 and 10.6 months (investigator) and 9.2, 9.3 and 8.9 months (BIRC), median time-to-progression (secondary endpoint) was 9.1, 9.0 and 16.4 months (investigator) and 9.3, 10.8 and 8.9 months (BIRC), respectively. Grade &gt;/= 3 AEs occurred in 80% and the most common were hypertension, stomatitis, anemia and fatigue. Fatal AE (epistaxis and acute respiratory failure; n = 2 each) was seen in four patients [ <ulink linkID=\"2692145\" linkType=\"Reference\">  2692145 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, a phase II trial (NCT04119453) for the treatment of adenoid cystic carcinoma was expected to complete in February 2024 [<ulink linkType=\"Reference\" linkID=\"2253691\">2253691</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3153",
              "name": "Adenoid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "04-Mar-2020",
            "endDate": "04-Sep-2027",
            "statusDate": "01-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Mar-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "25-Sep-2026",
                "successPercentage": "84%",
                "predictedDateL50": "10-Jan-2023",
                "predictedDateU50": "29-Aug-2024",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Sep-2026",
                "endDate": "26-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Jul-2025",
                "predictedDateU50": "03-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Apr-2027",
                "predictedDateU50": "04-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Planned",
                "milestoneDate": "09-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, the company was planning to file for Orphan Drug designation with the US FDA, for the treatment of ACC [<ulink linkType=\"Reference\" linkID=\"2253448\">2253448</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "08-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, the US FDA granted orphan drug designation for the treatment of adenoid cystic carcinoma [2403641].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, primary endpoint (ORR) from the phase II trial (NCT04119453) in 80 patients with patients with recurrent or metastatic adenoid cystic carcinoma were met. Across total patients, VEGFR-naïve and VEGFR-treated patients (n = 73, 60 and 13), objective response rates (ORR) (primary endpoint) and partial response (PR) rates were 15.1, 18.3 and 0% each (assessed by investigator) and 9.6, 8.3 and 15.4% each (assessed by blinded independent review committee, BIRC), respectively [ <ulink linkID=\"2692145\" linkType=\"Reference\">  2692145 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, top-line data of a phase II trial (NCT04119453) in 80 patients with patients with recurrent or metastatic adenoid cystic carcinoma were presented. Across total patients, VEGFR-naïve and VEGFR-treated patients (n = 73, 60 and 13), ORR and PR rates were 15.1, 18.3 and 0% each (assessed by investigator) and 9.6, 8.3 and 15.4% each (assessed by blinded independent review committee, BIRC), DCR were 64.4, 61.7 and 76.9% (investigator) and 65.8, 65.0 and 69.2% (BIRC), median PFS was 9.0, 9.0 and 10.6 months (investigator) and 9.2, 9.3 and 8.9 months (BIRC), median time-to-progression (secondary endpoint) was 9.1, 9.0 and 16.4 months (investigator) and 9.3, 10.8 and 8.9 months (BIRC), respectively. Grade &gt;/= 3 AEs occurred in 80% and the most common were hypertension, stomatitis, anemia and fatigue. Fatal AE (epistaxis and acute respiratory failure; n = 2 each) was seen in four patients [ <ulink linkID=\"2692145\" linkType=\"Reference\">  2692145 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, a phase II trial (NCT04119453) for the treatment of adenoid cystic carcinoma was expected to complete in February 2024 [<ulink linkType=\"Reference\" linkID=\"2253691\">2253691</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3658",
              "name": "Metastatic colorectal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Nov-2019",
            "endDate": "01-Mar-2028",
            "statusDate": "19-Jun-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "43%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Nov-2019",
                "endDate": "08-Oct-2024",
                "successPercentage": "77%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Oct-2024",
                "endDate": "03-Apr-2027",
                "successPercentage": "64%",
                "predictedDateL50": "11-Feb-2024",
                "predictedDateU50": "10-Apr-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Apr-2027",
                "endDate": "28-Jan-2028",
                "successPercentage": "88%",
                "predictedDateL50": "08-Mar-2026",
                "predictedDateU50": "21-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Oct-2027",
                "predictedDateU50": "01-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In August 2019, phase Ib/II (<ulink linkType=\"Protocol\" linkID=\"395914\">NCT04073615</ulink>; RM-110)  in patients with metastatic colorectal cancer was expected to complete in December 2020 [<ulink linkType=\"Reference\" linkID=\"2378859\">2378859</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Mar-2017",
            "endDate": "18-Sep-2028",
            "statusDate": "15-Jun-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "14-Mar-2017",
                "endDate": "30-Sep-2027",
                "successPercentage": "33%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Sep-2027",
                "endDate": "04-Aug-2028",
                "successPercentage": "94%",
                "predictedDateL50": "03-Feb-2027",
                "predictedDateU50": "14-Jan-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Apr-2028",
                "predictedDateU50": "18-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "27-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, preliminary review data of top-line results from ANGEL trial were reported [<ulink linkType=\"Reference\" linkID=\"2168808\">2168808</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In October 2018, topline unblinded efficacy and safety data from the phase III ANGEL trial in patients with advanced or metastatic gastric cancer were expected in the second half of 2019 [<ulink linkType=\"Reference\" linkID=\"2124002\">2124002</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "01-Mar-2016",
            "endDate": "14-Jun-2028",
            "statusDate": "24-Feb-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "32%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2016",
                "endDate": "14-Mar-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "14-Mar-2017",
                "endDate": "07-Jul-2027",
                "successPercentage": "34%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Jul-2027",
                "endDate": "06-May-2028",
                "successPercentage": "95%",
                "predictedDateL50": "21-Dec-2026",
                "predictedDateU50": "06-Oct-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-May-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "26-Jan-2028",
                "predictedDateU50": "14-Jun-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "27-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, preliminary review data of top-line results from ANGEL trial were reported [<ulink linkType=\"Reference\" linkID=\"2168808\">2168808</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In October 2018, topline unblinded efficacy and safety data from the phase III ANGEL trial in patients with advanced or metastatic gastric cancer were expected in the second half of 2019 [<ulink linkType=\"Reference\" linkID=\"2124002\">2124002</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Mar-2017",
            "endDate": "24-Nov-2024",
            "statusDate": "14-Feb-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "14-Mar-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "32%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "11-Oct-2024",
                "successPercentage": "93%",
                "predictedDateL50": "10-Apr-2023",
                "predictedDateU50": "15-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jul-2024",
                "predictedDateU50": "24-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In October 2018, an NDA for the drug for metastatic gastric cancer was expected to submit in late 2019 [<ulink linkType=\"Reference\" linkID=\"2124002\">2124002</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "27-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, preliminary review data of top-line results from ANGEL trial were reported [<ulink linkType=\"Reference\" linkID=\"2168808\">2168808</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In October 2018, topline unblinded efficacy and safety data from the phase III ANGEL trial in patients with advanced or metastatic gastric cancer were expected in the second half of 2019 [<ulink linkType=\"Reference\" linkID=\"2124002\">2124002</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In June 2019, regulatory approval by the FDA was expected in 2020 [ <ulink linkID=\"2160721\" linkType=\"Reference\"> 2160721 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1045600",
              "name": "Elevar Therapeutics Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Feb-2017",
            "endDate": "10-Feb-2029",
            "statusDate": "24-Feb-2017",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "29%",
            "timeToRegistration": "5.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Feb-2017",
                "endDate": "17-Nov-2027",
                "successPercentage": "32%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "10.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Nov-2027",
                "endDate": "16-Dec-2028",
                "successPercentage": "92%",
                "predictedDateL50": "18-Mar-2027",
                "predictedDateU50": "23-May-2028",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Dec-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Aug-2028",
                "predictedDateU50": "10-Feb-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "27-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, preliminary review data of top-line results from ANGEL trial were reported [<ulink linkType=\"Reference\" linkID=\"2168808\">2168808</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In October 2018, topline unblinded efficacy and safety data from the phase III ANGEL trial in patients with advanced or metastatic gastric cancer were expected in the second half of 2019 [<ulink linkType=\"Reference\" linkID=\"2124002\">2124002</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "55266",
        "displayName": "zolbetuximab",
        "drugPrograms": [
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Apr-2019",
            "endDate": "20-Nov-2024",
            "statusDate": "31-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "19-Apr-2019",
                "endDate": "31-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2023",
                "endDate": "16-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-May-2024",
                "predictedDateU50": "20-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, primary and secondary endpoints from phase III trial (NCT03504397) were met [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "31-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the NMPA accepted the BLA for for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative GEJ adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"3029687\" linkType=\"Reference\"> 3029687 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2009",
            "endDate": "17-Feb-2025",
            "statusDate": "13-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2009",
                "endDate": "08-Sep-2010",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "08-Sep-2010",
                "endDate": "31-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "13-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jul-2023",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Sep-2024",
                "predictedDateU50": "17-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "18-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, final data from the FAST trial were published. In the overall population, both PFS (7.5 vs 5.3 months) and OS (13 vs 8.3 months) were significantly improved with zolbetuximab + EOX compared with EOX alone. This significant PFS benefit was retained in patients with moderate-to-strong CLDN18.2 expression in ≥70% of tumor cells (9 vs 5.7 months) but not in low CLDN18.2-expressing patients (4.3 vs 4.1 months) [ <ulink linkID=\"2445147\" linkType=\"Reference\">  2445147 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, primary and secondary endpoints from phase III trial (NCT03504397) were met [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "13-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In June 2023, approval from the EMA fore MAA of zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and subsequent European Commission (EC) decision was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In June 2023, approval from the EMA fore MAA of zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and subsequent European Commission (EC) decision was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the EMA regarding the MAA for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2018",
            "endDate": "14-May-2024",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "09-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2023",
                "endDate": "08-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jan-2024",
                "predictedDateU50": "14-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, primary and secondary endpoints from phase III trial (NCT03504397) were met [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "09-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the company filed an NDA to MHLW for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"2970508\" linkType=\"Reference\"> 2970508 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2018",
            "endDate": "28-Mar-2026",
            "statusDate": "23-Oct-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "2.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Jun-2018",
                "endDate": "23-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Oct-2018",
                "endDate": "30-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Apr-2025",
                "endDate": "23-Feb-2026",
                "successPercentage": "95%",
                "predictedDateL50": "04-Feb-2025",
                "predictedDateU50": "25-Jun-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Feb-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Nov-2025",
                "predictedDateU50": "28-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, primary and secondary endpoints from phase III trial (NCT03504397) were met [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III trial (NCT03653507) in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma was expected to complete in April 2025 [ <ulink linkID=\"2119719\" linkType=\"Reference\"> 2119719 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Priority Review",
            "startDate": "31-Jan-2018",
            "endDate": "25-Feb-2024",
            "statusDate": "06-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "06-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jul-2023",
                "endDate": "26-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Nov-2023",
                "predictedDateU50": "25-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, the US FDA granted Fast Track designation to the drug for treatment of gastric and gastroesophageal junction [ <ulink linkID=\"2761063\" linkType=\"Reference\">  2761063 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, primary and secondary endpoints from phase III trial (NCT03504397) were met [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2119719\" linkType=\"Reference\"> 2119719 </ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "06-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company's Biologics Licence Application (BLA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma has been accepted by the US FDA and granted Priority Review based on the results from both the phase III (SPOTLIGHT and GLOW) trials [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "06-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company's Biologics Licence Application (BLA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma has been accepted by the US FDA and granted Priority Review based on the results from both the phase III (SPOTLIGHT and GLOW) trials [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023 [ <ulink linkID=\"2029605\" linkType=\"Reference\"> 2029605 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "12-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company set a PDUFA target action date on January 12, 2024 for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Apr-2019",
            "endDate": "17-Nov-2024",
            "statusDate": "31-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "19-Apr-2019",
                "endDate": "31-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Jul-2023",
                "endDate": "15-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Sep-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-May-2024",
                "predictedDateU50": "17-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "31-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the NMPA accepted the BLA for for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative GEJ adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"3029687\" linkType=\"Reference\"> 3029687 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-May-2009",
            "endDate": "15-Feb-2025",
            "statusDate": "13-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-May-2009",
                "endDate": "08-Sep-2010",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "08-Sep-2010",
                "endDate": "31-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "13-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jul-2023",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Sep-2024",
                "predictedDateU50": "15-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "13-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the European Medicines Agency (EMA) accepted the marketing authorization application (MAA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In June 2023, approval from the EMA fore MAA of zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and subsequent European Commission (EC) decision was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In June 2023, approval from the EMA fore MAA of zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive and subsequent European Commission (EC) decision was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Planned",
                "milestoneDate": "31-Dec-2024",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of the EMA regarding the MAA for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive was expected in 2024 [ <ulink linkID=\"3011044\" linkType=\"Reference\"> 3011044 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2018",
            "endDate": "08-May-2024",
            "statusDate": "09-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "09-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2023",
                "endDate": "07-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "08-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "09-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the company filed an NDA to MHLW for first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive [ <ulink linkID=\"2970508\" linkType=\"Reference\"> 2970508 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2018",
            "endDate": "24-Mar-2026",
            "statusDate": "23-Oct-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "2.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "29-Jun-2018",
                "endDate": "23-Oct-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Oct-2018",
                "endDate": "30-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Apr-2025",
                "endDate": "21-Feb-2026",
                "successPercentage": "95%",
                "predictedDateL50": "29-Jan-2025",
                "predictedDateU50": "12-Jul-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Feb-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Nov-2025",
                "predictedDateU50": "24-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [<ulink linkType=\"Reference\" linkID=\"2119719\">2119719</ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023  [<ulink linkType=\"Reference\" linkID=\"2029605\">2029605</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2025",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, a phase III trial (NCT03653507) in metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma was expected to complete in April 2025 [ <ulink linkID=\"2119719\" linkType=\"Reference\"> 2119719 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3667",
              "name": "Metastatic esophageal cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Priority Review",
            "startDate": "31-Jan-2018",
            "endDate": "25-Feb-2024",
            "statusDate": "06-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "31-Jan-2018",
                "endDate": "06-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jul-2023",
                "endDate": "26-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Nov-2023",
                "predictedDateU50": "25-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "30-Sep-2022",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, the US FDA granted Fast Track designation to the drug for treatment of gastric and gastroesophageal junction [ <ulink linkID=\"2761063\" linkType=\"Reference\">  2761063 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "16-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, topline data from the phase III SPOTLIGHT trial (NCT03504397) for first-line treatment of patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported, showing that the trial met its primary and secondary endpoints with significant improvements seen in progression-free survival and overall survival for zolbetuximab plus mFOLFOX6 compared with placebo plus mFOLFOX6 [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, positive topline data from phase III trial (NCT03504397) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2773790\" linkType=\"Reference\">  2773790 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, positive topline results from phase III (NCT03653507; GLOW) study for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced un-resectable or metastatic gastric or gastroesophageal junction adenocarcinoma were reported [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "15-Dec-2022",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, the primary and key secondary endpoints from the phase III (NCT03653507; GLOW) study, for the treatment of Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma were met [  <ulink linkID=\"2792508\" linkType=\"Reference\">  2792508  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In May 2021, filing for gastric and gastroesophageal junction adenocarcinoma was expected in fiscal year 2022 [  <ulink linkID=\"2462197\" linkType=\"Reference\">  2462197 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Sep-2023",
                "notes": "In February 2023, first BLA filing, presumably for filing for gastric and gastroesophageal junction adenocarcinoma was expected in 1HFY23 [ <ulink linkID=\"2818635\" linkType=\"Reference\">  2818635 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Jul-2023",
                "notes": "In December 2020, the phase III Glow trial (NCT03653507) of zolbetuximab in combination with CAPOX in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in July 2023 [ <ulink linkID=\"2119719\" linkType=\"Reference\"> 2119719 </ulink>]].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "06-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company's Biologics Licence Application (BLA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma has been accepted by the US FDA and granted Priority Review based on the results from both the phase III (SPOTLIGHT and GLOW) trials [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "06-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company's Biologics Licence Application (BLA) for zolbetuximab for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma has been accepted by the US FDA and granted Priority Review based on the results from both the phase III (SPOTLIGHT and GLOW) trials [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, the phase III SPOTLIGHT trial (NCT03504397) of zolbetuximab in combination with mFOLFOX6 in Claudin 18.2 positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma was expected to complete in December 2023 [ <ulink linkID=\"2029605\" linkType=\"Reference\"> 2029605 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "12-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the company set a PDUFA target action date on January 12, 2024 for the first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative stomach or gastroesophageal junction (GEJ) adenocarcinoma [ <ulink linkID=\"3000647\" linkType=\"Reference\"> 3000647 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2019",
            "endDate": "",
            "statusDate": "14-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Feb-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2019",
            "endDate": "",
            "statusDate": "14-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Feb-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2019",
            "endDate": "",
            "statusDate": "14-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Feb-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1013295",
              "name": "Astellas Pharma Inc"
            },
            "indication": {
              "id": "3669",
              "name": "Metastatic pancreas cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jan-2014",
            "endDate": "",
            "statusDate": "14-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "13-Jan-2014",
                "endDate": "14-Feb-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "14-Feb-2019",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "64948",
        "displayName": "dupilumab",
        "drugPrograms": [
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "29",
              "name": "Aspergillus infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Sep-2020",
            "endDate": "29-Jun-2025",
            "statusDate": "17-May-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "56%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Sep-2020",
                "endDate": "28-Jul-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jul-2024",
                "endDate": "26-May-2025",
                "successPercentage": "91%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "25-Nov-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Feb-2025",
                "predictedDateU50": "29-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "128",
              "name": "Gastritis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-May-2021",
            "endDate": "17-Jun-2027",
            "statusDate": "04-May-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-May-2021",
                "endDate": "03-May-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-May-2023",
                "endDate": "30-Jul-2026",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Jul-2026",
                "endDate": "17-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Jul-2025",
                "predictedDateU50": "13-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2027",
                "predictedDateU50": "17-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2024",
                "milestoneExtendedDate": "31-Jul-2024",
                "notes": "In September 2019, a phase II study evaluating dupilumab in patients with eosinophilic gastritis (NCT03678545) was expected to begin in May 2020 and to complete in July 2024 [ <ulink linkID=\"2074955\" linkType=\"Reference\">  2074955 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "276",
              "name": "Prostate tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jul-2019",
            "endDate": "30-Mar-2028",
            "statusDate": "04-Jul-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "15%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Jul-2019",
                "endDate": "17-Oct-2024",
                "successPercentage": "49%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "17-Oct-2024",
                "endDate": "08-Jun-2027",
                "successPercentage": "35%",
                "predictedDateL50": "10-Feb-2024",
                "predictedDateU50": "24-Mar-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "08-Jun-2027",
                "endDate": "21-Feb-2028",
                "successPercentage": "86%",
                "predictedDateL50": "22-Apr-2026",
                "predictedDateU50": "31-Oct-2027",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Nov-2027",
                "predictedDateU50": "30-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2021",
            "endDate": "12-Nov-2026",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "78%",
            "timeToRegistration": "2.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Nov-2021",
                "endDate": "13-Jun-2025",
                "successPercentage": "82%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2025",
                "endDate": "22-Aug-2026",
                "successPercentage": "95%",
                "predictedDateL50": "16-Nov-2024",
                "predictedDateU50": "02-Nov-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Aug-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Apr-2026",
                "predictedDateU50": "12-Nov-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "22-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, an implied trial approval was granted in China for adjuvant therapy (CPUO) in adult patients with unexplained chronic pruritus refractory to antihistamine therapy [ <ulink linkID=\"2610085\" linkType=\"Reference\">  2610085 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In March 202, a phase III trial (NCT05263206) was expected to complete in June 2025 in in adult patients with chronic pruritus of unknown origin [ <ulink linkID=\"2635350\" linkType=\"Reference\">  2635350 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2021",
            "endDate": "01-Jun-2026",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "72%",
            "timeToRegistration": "2.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Nov-2021",
                "endDate": "13-Jun-2025",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2025",
                "endDate": "19-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "01-Dec-2024",
                "predictedDateU50": "30-Sep-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Apr-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jan-2026",
                "predictedDateU50": "01-Jun-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In March 202, a phase III trial (NCT05263206) was expected to complete in June 2025 in in adult patients with chronic pruritus of unknown origin [ <ulink linkID=\"2635350\" linkType=\"Reference\">  2635350 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2021",
            "endDate": "23-May-2026",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "2.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Nov-2021",
                "endDate": "13-Jun-2025",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2025",
                "endDate": "13-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "10-Dec-2024",
                "predictedDateU50": "03-Sep-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Apr-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2026",
                "predictedDateU50": "23-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In March 202, a phase III trial (NCT05263206) was expected to complete in June 2025 in in adult patients with chronic pruritus of unknown origin [ <ulink linkID=\"2635350\" linkType=\"Reference\">  2635350 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2021",
            "endDate": "22-May-2026",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "75%",
            "timeToRegistration": "2.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Nov-2021",
                "endDate": "13-Jun-2025",
                "successPercentage": "79%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2025",
                "endDate": "13-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "20-Oct-2024",
                "predictedDateU50": "22-Nov-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Apr-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2026",
                "predictedDateU50": "22-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In March 202, a phase III trial (NCT05263206) was expected to complete in June 2025 in in adult patients with chronic pruritus of unknown origin [ <ulink linkID=\"2635350\" linkType=\"Reference\">  2635350 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2021",
            "endDate": "22-Aug-2026",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "78%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Nov-2021",
                "endDate": "13-Jun-2025",
                "successPercentage": "82%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2025",
                "endDate": "03-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "15-Oct-2024",
                "predictedDateU50": "19-Nov-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Feb-2026",
                "predictedDateU50": "22-Aug-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "13-Jun-2025",
                "milestoneExtendedDate": "",
                "notes": "In March 202, a phase III trial (NCT05263206) was expected to complete in June 2025 in in adult patients with chronic pruritus of unknown origin [ <ulink linkID=\"2635350\" linkType=\"Reference\">  2635350 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "337",
              "name": "Ulcerative colitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "12-Jan-2023",
            "endDate": "27-Nov-2028",
            "statusDate": "12-Jan-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "14%",
            "timeToRegistration": "4.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "12-Jan-2023",
                "endDate": "02-May-2025",
                "successPercentage": "52%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2025",
                "endDate": "21-Dec-2027",
                "successPercentage": "29%",
                "predictedDateL50": "19-Jun-2024",
                "predictedDateU50": "14-Sep-2025",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Dec-2027",
                "endDate": "19-Oct-2028",
                "successPercentage": "91%",
                "predictedDateL50": "03-Nov-2026",
                "predictedDateU50": "16-May-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Oct-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jul-2028",
                "predictedDateU50": "27-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "14-Apr-2025",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, phase II trial ( NCT05731128) for ulcerative colitis was expected to complete in April 2025 [ <ulink linkID=\"2825415\" linkType=\"Reference\">  2825415 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "24-Apr-2020",
            "endDate": "26-May-2026",
            "statusDate": "24-Apr-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "2.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "24-Apr-2020",
                "endDate": "16-Dec-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Dec-2024",
                "endDate": "05-Mar-2026",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jun-2024",
                "predictedDateU50": "06-Apr-2025",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Mar-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Oct-2025",
                "predictedDateU50": "26-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In April 2020, the phase III trial (CUPID) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in July 2021 in China [ <ulink linkID=\"2247259\" linkType=\"Reference\">  2247259 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2021, data from part B of the phase III CUPID trial (NCT04180488) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine were expected in 1H22 [ <ulink linkID=\"2556507\" linkType=\"Reference\">  2556507 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2023, results from a phase III trial (NCT04180488; LIBERTY-CSU CUPID) evaluating efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine and are omalizumab naïve were expected in late 2024 [ <ulink linkID=\"3476491\" linkType=\"Reference\"> 3476491 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Dec-2020",
            "endDate": "27-Mar-2024",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2020",
                "endDate": "31-Mar-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Mar-2023",
                "endDate": "26-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jan-2024",
                "predictedDateU50": "27-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2021, data from part B of the phase III CUPID trial (NCT04180488) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine were expected in 1H22 [ <ulink linkID=\"2556507\" linkType=\"Reference\">  2556507 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PMDA NDA Filing Accepted",
                "status": "Positive Opinion",
                "milestoneDate": "31-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, regulatory application was submitted in Japan for chronic spontaneous urticaria [ <ulink linkID=\"2911657\" linkType=\"Reference\"> 2911657 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT04681729 trial in patients with chronic inducable cold urticaria were expected by in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "04-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, phase III trial (NCT04681729) did not meet its efficacy endpoints [ <ulink linkID=\"2921417\" linkType=\"Reference\"> 2921417 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "09-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, phase III LIBERTY-CINDU CurIADS trial (NCT04681729) of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in May 2023 [  <ulink linkID=\"2406201\" linkType=\"Reference\">   2406201  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Dec-2019",
            "endDate": "24-May-2024",
            "statusDate": "07-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "11-Dec-2019",
                "endDate": "07-Mar-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2023",
                "endDate": "24-Apr-2024",
                "successPercentage": "24%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Mar-2024",
                "predictedDateU50": "24-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In February 2020, the phase III trial (CUPID) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in July 2021 [ <ulink linkID=\"2247259\" linkType=\"Reference\">  2247259 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In January 2021, the company expected to submit marketing application filings for chronic inducible and chronic spontaneous urticaria in 2022 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2021, data from part B of the phase III CUPID trial (NCT04180488) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine were expected in 1H22 [ <ulink linkID=\"2556507\" linkType=\"Reference\">  2556507 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "18-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, negative interim data from CUPID part B were reported showing that the study missed its primary endpoints, and the study stopped due to futility [ <ulink linkID=\"2618510\" linkType=\"Reference\">  2618510 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "18-Feb-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2022, negative interim data from CUPID part B were reported showing that the study missed its primary endpoints, and the study stopped due to futility [ <ulink linkID=\"2618510\" linkType=\"Reference\">  2618510 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2022",
                "milestoneExtendedDate": "31-Oct-2022",
                "notes": "In December 2020, the phase III LIBERTY-CINDU CurIADS trial (NCT04681729) assessing dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in October 2022 [ <ulink linkID=\"2406201\" linkType=\"Reference\">  2406201 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In June 2022, phase III LIBERTY-CINDU CurIADS trial (NCT04681729) data of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1 antihistamine were expected for 1H23 [  <ulink linkID=\"2406201\" linkType=\"Reference\">   2406201  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "07-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, the sBLA for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) was accepted for review by the US FDA [  <ulink linkID=\"2848113\" linkType=\"Reference\">  2848113 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT04681729 trial in patients with chronic inducable cold urticaria were expected by in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "04-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, phase III trial (NCT04681729) did not meet its efficacy endpoints [ <ulink linkID=\"2921417\" linkType=\"Reference\"> 2921417 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "09-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, phase III LIBERTY-CINDU CurIADS trial (NCT04681729) of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in May 2023 [  <ulink linkID=\"2406201\" linkType=\"Reference\">   2406201  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Complete Response Letter",
                "status": "Negative Outcome",
                "milestoneDate": "20-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, complete response letter was issued by the FDA for the sBLA in chronic spontaneous urticaria stating requirement of additional efficacy data to support approval [ <ulink linkID=\"3476491\" linkType=\"Reference\"> 3476491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (sNDA/sBLA)",
                "status": "Planned",
                "milestoneDate": "22-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, an sBLA for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) was set with PDUFA target action date of October 22, 2023 [  <ulink linkID=\"2848113\" linkType=\"Reference\">  2848113 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Dec-2018",
            "endDate": "18-Nov-2025",
            "statusDate": "31-Dec-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "10%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Dec-2018",
                "endDate": "31-Dec-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2019",
                "endDate": "29-Aug-2024",
                "successPercentage": "10%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Aug-2024",
                "endDate": "23-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "24-Jan-2024",
                "predictedDateU50": "12-Jan-2025",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-May-2025",
                "predictedDateU50": "18-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2021",
                "milestoneExtendedDate": "31-May-2021",
                "notes": "In November 2018, a phase II trial was expected to complete on May, 2021 [ <ulink linkID=\"2097518\" linkType=\"Reference\">  2097518 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, positive topline data from study A  of the phase III CUPID trial (NCT04180488) in biologic-naive adult and adolescent participants with chronic spontaneous urticaria were reported, showing that <b> </b>the trial met primary and all key secondary endpoints at 24 weeks and that dupilumab  nearly doubled reduction in itch and urticaria activity scores compared with antihistamines alone at 24 weeks (reduction in itch severity was 63 versus 35% and reduction in urticaria activity severity was 63 versus 37%) [ <ulink linkID=\"2501183\" linkType=\"Reference\">  2501183 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In October 2021, data from part B of the phase III CUPID trial (NCT04180488) assessing dupilumab in adult and adolescent participants with chronic spontaneous urticaria who remain symptomatic despite the use of H1 antihistamine were expected in 1H22 [ <ulink linkID=\"2556507\" linkType=\"Reference\">  2556507 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT04681729 trial in patients with chronic inducable cold urticaria were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "04-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, phase III trial (NCT04681729) did not meet its efficacy endpoints [ <ulink linkID=\"2921417\" linkType=\"Reference\"> 2921417 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "09-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, phase III LIBERTY-CINDU CurIADS trial (NCT04681729) of dupilumab in patients with chronic inducible cold urticaria who remain symptomatic despite the use of H1 antihistamine was expected to complete in May 2023 [  <ulink linkID=\"2406201\" linkType=\"Reference\">   2406201  </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In October 2023, results from a phase III trial (NCT04180488; LIBERTY-CSU CUPID) evaluating efficacy of dupilumab in study participants with CSU who remain symptomatic despite the use of H1 antihistamine and are omalizumab naïve were expected in late 2024 [ <ulink linkID=\"3476491\" linkType=\"Reference\"> 3476491 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Oct-2013",
            "endDate": "",
            "statusDate": "31-Oct-2013",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Oct-2013",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1107",
              "name": "Allergic rhinitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Jun-2018",
            "endDate": "14-Jul-2025",
            "statusDate": "14-Jun-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "88%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Jun-2018",
                "endDate": "24-Sep-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Sep-2018",
                "endDate": "17-Aug-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Aug-2024",
                "endDate": "11-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "02-Feb-2024",
                "predictedDateU50": "13-Dec-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Feb-2025",
                "predictedDateU50": "14-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "13-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, the phase II study evaluating dupilumab as an adjunct to timothy grass sc immunotherapy (SCIT) in patients with allergic rhinitis (NCT03558997) was complete [ <ulink linkID=\"2050414\" linkType=\"Reference\">  2050414 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Apr-2019",
            "endDate": "13-Jun-2025",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Apr-2019",
                "endDate": "22-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2024",
                "endDate": "18-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Oct-2023",
                "predictedDateU50": "03-Jun-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Dec-2024",
                "predictedDateU50": "13-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2019, the phase III BOREAS trial (NCT03930732) evaluating the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation was expected to complete in April 2022 [ <ulink linkID=\"2149324\" linkType=\"Reference\">  2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, pivotal data from phase III trial of dupilumab in COPD patients were expected in 2023 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, primary endpoint of a phase III trial (NCT03930732; BOREAS) were met [ <ulink linkID=\"2868815\" linkType=\"Reference\"> 2868815 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT03930732 trial in patients with chronic obstructive pulmonary disorder were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial ( NCT03930732) was expected to complete in May 2023 [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT03930732) in COPD was completed [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "21-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03930732) in COPD demonstrating 0.78 and 1.10 annualized rate of moderate or severe exacerbations with dupilumab and placebo, respectively, 160 ml and 77 ml least-squares (LS) mean prebronchodilator FEV1 increase from baseline to week 12 in dupilumab and placebo, respectively, which was sustained through week 52, SGRQ score improvement by an LS mean of -9.7 and -6.4 in dupilumab and placebo, respectively, along with E-RS-COPD score improvement by LS mean of -2.7 and -1.6 in dupilumab and placebo, respectively at week 52 [ <ulink linkID=\"2957868\" linkType=\"Reference\"> 2957868 </ulink> ], [ <ulink linkID=\"2951135\" linkType=\"Reference\"> 2951135 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Apr-2019",
            "endDate": "30-Jan-2025",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Apr-2019",
                "endDate": "22-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2024",
                "endDate": "31-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "27-Oct-2023",
                "predictedDateU50": "03-Jun-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "31-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Sep-2024",
                "predictedDateU50": "30-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2019, the phase III BOREAS trial (NCT03930732) evaluating the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation was expected to complete in April 2022 [ <ulink linkID=\"2149324\" linkType=\"Reference\">  2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, pivotal data from phase III trial of dupilumab in COPD patients were expected in 2023 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, primary endpoint of a phase III trial (NCT03930732; BOREAS) were met [ <ulink linkID=\"2868815\" linkType=\"Reference\"> 2868815 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT03930732 trial in patients with chronic obstructive pulmonary disorder were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT03930732) in COPD was completed [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial ( NCT03930732) was expected to complete in May 2023 [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "21-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03930732) in COPD demonstrating 0.78 and 1.10 annualized rate of moderate or severe exacerbations with dupilumab and placebo, respectively, 160 ml and 77 ml least-squares (LS) mean prebronchodilator FEV1 increase from baseline to week 12 in dupilumab and placebo, respectively, which was sustained through week 52, SGRQ score improvement by an LS mean of -9.7 and -6.4 in dupilumab and placebo, respectively, along with E-RS-COPD score improvement by LS mean of -2.7 and -1.6 in dupilumab and placebo, respectively at week 52 [ <ulink linkID=\"2957868\" linkType=\"Reference\"> 2957868 </ulink> ], [ <ulink linkID=\"2951135\" linkType=\"Reference\"> 2951135 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Apr-2019",
            "endDate": "29-Jan-2025",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Apr-2019",
                "endDate": "22-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2024",
                "endDate": "30-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "24-Nov-2023",
                "predictedDateU50": "20-May-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Sep-2024",
                "predictedDateU50": "29-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2019, the phase III BOREAS trial (NCT03930732) evaluating the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation was expected to complete in April 2022 [ <ulink linkID=\"2149324\" linkType=\"Reference\">  2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, pivotal data from phase III trial of dupilumab in COPD patients were expected in 2023 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, primary endpoint of a phase III trial (NCT03930732; BOREAS) were met [ <ulink linkID=\"2868815\" linkType=\"Reference\"> 2868815 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT03930732 trial in patients with chronic obstructive pulmonary disorder were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial ( NCT03930732) was expected to complete in May 2023 [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT03930732) in COPD was completed [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "21-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03930732) in COPD demonstrating 0.78 and 1.10 annualized rate of moderate or severe exacerbations with dupilumab and placebo, respectively, 160 ml and 77 ml least-squares (LS) mean prebronchodilator FEV1 increase from baseline to week 12 in dupilumab and placebo, respectively, which was sustained through week 52, SGRQ score improvement by an LS mean of -9.7 and -6.4 in dupilumab and placebo, respectively, along with E-RS-COPD score improvement by LS mean of -2.7 and -1.6 in dupilumab and placebo, respectively at week 52 [ <ulink linkID=\"2957868\" linkType=\"Reference\"> 2957868 </ulink> ], [ <ulink linkID=\"2951135\" linkType=\"Reference\"> 2951135 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "designation": "Breakthrough Therapy",
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Apr-2019",
            "endDate": "19-Apr-2025",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Apr-2019",
                "endDate": "22-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2024",
                "endDate": "10-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "14-Oct-2023",
                "predictedDateU50": "06-Jul-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Nov-2024",
                "predictedDateU50": "19-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2019, the phase III BOREAS trial (NCT03930732) evaluating the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation was expected to complete in April 2022 [ <ulink linkID=\"2149324\" linkType=\"Reference\">  2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, pivotal data from phase III trial of dupilumab in COPD patients were expected in 2023 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, primary endpoint of a phase III trial (NCT03930732; BOREAS) were met [ <ulink linkID=\"2868815\" linkType=\"Reference\"> 2868815 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT03930732 trial in patients with chronic obstructive pulmonary disorder were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT03930732) in COPD was completed [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial ( NCT03930732) was expected to complete in May 2023 [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "21-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03930732) in COPD demonstrating 0.78 and 1.10 annualized rate of moderate or severe exacerbations with dupilumab and placebo, respectively, 160 ml and 77 ml least-squares (LS) mean prebronchodilator FEV1 increase from baseline to week 12 in dupilumab and placebo, respectively, which was sustained through week 52, SGRQ score improvement by an LS mean of -9.7 and -6.4 in dupilumab and placebo, respectively, along with E-RS-COPD score improvement by LS mean of -2.7 and -1.6 in dupilumab and placebo, respectively at week 52 [ <ulink linkID=\"2957868\" linkType=\"Reference\"> 2957868 </ulink> ], [ <ulink linkID=\"2951135\" linkType=\"Reference\"> 2951135 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "2564",
              "name": "Alopecia areata"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Apr-2023",
            "endDate": "08-Apr-2029",
            "statusDate": "10-Apr-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "23%",
            "timeToRegistration": "5.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Apr-2023",
                "endDate": "26-Aug-2025",
                "successPercentage": "63%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "26-Aug-2025",
                "endDate": "10-May-2028",
                "successPercentage": "40%",
                "predictedDateL50": "24-Jul-2024",
                "predictedDateU50": "24-Jan-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-May-2028",
                "endDate": "06-Mar-2029",
                "successPercentage": "93%",
                "predictedDateL50": "23-Mar-2027",
                "predictedDateU50": "18-Oct-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Mar-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Nov-2028",
                "predictedDateU50": "08-Apr-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "31-Mar-2025",
                "milestoneExtendedDate": "",
                "notes": "In September 2022, a phase II trial (NCT05551793) was expected to be completed in March 2025 in patients with alopecia areata [ <ulink linkID=\"2743678\" linkType=\"Reference\">  2743678 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "3000",
              "name": "Chronic sinusitis"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "18-Feb-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "3208",
              "name": "Nasal polyps"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-May-2023",
            "endDate": "09-Mar-2027",
            "statusDate": "16-May-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "3.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-May-2023",
                "endDate": "21-Nov-2025",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Nov-2025",
                "endDate": "04-Jan-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Oct-2024",
                "predictedDateU50": "04-Apr-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Jan-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Aug-2026",
                "predictedDateU50": "09-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "3615",
              "name": "Peanut hypersensitivity"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Oct-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "3846",
              "name": "Prurigo nodularis"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Apr-2020",
            "endDate": "19-Apr-2024",
            "statusDate": "07-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "29-Apr-2020",
                "endDate": "07-Mar-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Mar-2023",
                "endDate": "13-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "19-Apr-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "14-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, an IND was filed in China [ <ulink linkID=\"2338501\" linkType=\"Reference\">  2338501 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "27-Oct-2020",
                "milestoneExtendedDate": "",
                "notes": "In October 2020, an IND was filed in China [ <ulink linkID=\"2338501\" linkType=\"Reference\">  2338501 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In April 2020, the phase III trial (PRIME) assessing dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable was expected to complete in July 2021 in China [ <ulink linkID=\"2247269\" linkType=\"Reference\">  2247269 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Oct-2021",
                "notes": "In September 2020, the phase III trial (PRIME) assessing dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable was expected to complete in October 2021 [ <ulink linkID=\"2247269\" linkType=\"Reference\">  2247269 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In January 2021, data from phase III trial of dupilumab in patients with prurigo nodularis were expected within 'the next 12-18 months' [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "27-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, an IND for dupilumab was filed in China [ <ulink linkID=\"2744385\" linkType=\"Reference\">  2744385 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "3846",
              "name": "Prurigo nodularis"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "19-Mar-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "6187",
              "name": "Bullous pemphigoid"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "06-Feb-2020",
            "endDate": "06-Jun-2025",
            "statusDate": "06-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "48%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "06-Feb-2020",
                "endDate": "05-Aug-2024",
                "successPercentage": "50%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2024",
                "endDate": "07-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "07-Feb-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jan-2025",
                "predictedDateU50": "06-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "17-Mar-2020",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, the phase II/III trial (LIBERTY-BP) assessing dupilumab in adult patients with bullous pemphigoid was expected to begin in March 2020 [ <ulink linkID=\"2247258\" linkType=\"Reference\">  2247258 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "04-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, the phase II/III trial (LIBERTY-BP) assessing dupilumab in adult patients with bullous pemphigoid was expected to complete in August 2022 [ <ulink linkID=\"2247258\" linkType=\"Reference\">  2247258 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "indication": {
              "id": "6187",
              "name": "Bullous pemphigoid"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Feb-2020",
            "endDate": "05-Aug-2025",
            "statusDate": "06-Feb-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "37%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "06-Feb-2020",
                "endDate": "05-Aug-2024",
                "successPercentage": "39%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2024",
                "endDate": "30-Jun-2025",
                "successPercentage": "94%",
                "predictedDateL50": "01-Feb-2024",
                "predictedDateU50": "07-Feb-2025",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Mar-2025",
                "predictedDateU50": "05-Aug-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "29",
              "name": "Aspergillus infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "17-May-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "128",
              "name": "Gastritis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "04-May-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "276",
              "name": "Prostate tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "04-Jul-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "279",
              "name": "Pruritus"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "11-Nov-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "337",
              "name": "Ulcerative colitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "12-Jan-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "24-Apr-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Mar-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "07-Mar-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "340",
              "name": "Urticaria"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Dec-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1102",
              "name": "Atopic dermatitis"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "31-Oct-2013",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1107",
              "name": "Allergic rhinitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "14-Jun-2018",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "15-Apr-2019",
            "endDate": "17-Dec-2024",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "15-Apr-2019",
                "endDate": "22-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Mar-2024",
                "endDate": "16-Nov-2024",
                "successPercentage": "95%",
                "predictedDateL50": "27-Nov-2023",
                "predictedDateU50": "19-Jun-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "16-Nov-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Aug-2024",
                "predictedDateU50": "17-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Apr-2022",
                "notes": "In April 2019, the phase III BOREAS trial (NCT03930732) evaluating the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe COPD with type 2 inflammation was expected to complete in April 2022 [ <ulink linkID=\"2149324\" linkType=\"Reference\">  2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In January 2021, pivotal data from phase III trial of dupilumab in COPD patients were expected in 2023 [ <ulink linkID=\"2391235\" linkType=\"Reference\">  2391235 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "23-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, primary endpoint of a phase III trial (NCT03930732; BOREAS) were met [ <ulink linkID=\"2868815\" linkType=\"Reference\"> 2868815 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In December 2022, data from the phase III NCT03930732 trial in patients with chronic obstructive pulmonary disorder were expected in 1H23 [ <ulink linkID=\"2817899\" linkType=\"Reference\">  2817899 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, a phase III trial (NCT03930732) in COPD was completed [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2022, a phase III trial ( NCT03930732) was expected to complete in May 2023 [ <ulink linkID=\"2149324\" linkType=\"Reference\"> 2149324 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Positive Outcome",
                "milestoneDate": "21-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, positive data from the phase III trial (NCT03930732) in COPD demonstrating 0.78 and 1.10 annualized rate of moderate or severe exacerbations with dupilumab and placebo, respectively, 160 ml and 77 ml least-squares (LS) mean prebronchodilator FEV1 increase from baseline to week 12 in dupilumab and placebo, respectively, which was sustained through week 52, SGRQ score improvement by an LS mean of -9.7 and -6.4 in dupilumab and placebo, respectively, along with E-RS-COPD score improvement by LS mean of -2.7 and -1.6 in dupilumab and placebo, respectively at week 52 [ <ulink linkID=\"2957868\" linkType=\"Reference\"> 2957868 </ulink> ], [ <ulink linkID=\"2951135\" linkType=\"Reference\"> 2951135 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Breakthrough Therapy",
                "status": "Granted",
                "milestoneDate": "30-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "By June 2023, the FDA granted breakthrough therapy to dupilumab for uncontrolled COPD with an eosinophilic phenotype based on phase III BOREAS data [ <ulink linkID=\"3033220\" linkType=\"Reference\"> 3033220 </ulink>], [ <ulink linkID=\"3033741\" linkType=\"Reference\"> 3033741 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "31-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2020, a marketing application for COPD was expected to submit in2023 and beyond [ <ulink linkID=\"2242454\" linkType=\"Reference\">  2242454 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1185",
              "name": "Chronic obstructive pulmonary disease"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "15-Apr-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1296",
              "name": "Keratoconjunctivitis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Feb-2020",
            "endDate": "07-May-2028",
            "statusDate": "10-Feb-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "10-Feb-2020",
                "endDate": "04-Oct-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-Oct-2024",
                "endDate": "19-Jun-2027",
                "successPercentage": "40%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "26-Mar-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Jun-2027",
                "endDate": "06-Apr-2028",
                "successPercentage": "93%",
                "predictedDateL50": "01-May-2026",
                "predictedDateU50": "27-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Dec-2027",
                "predictedDateU50": "07-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2021",
                "milestoneExtendedDate": "31-Aug-2021",
                "notes": "In March 2020, a phase II study (NCT04296864) was expected to complete in August 2021 in patients with atopic keratoconjunctivitis [ <ulink linkID=\"2252698\" linkType=\"Reference\">  2252698 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "2564",
              "name": "Alopecia areata"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "10-Apr-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3000",
              "name": "Chronic sinusitis"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Dec-2020",
            "endDate": "28-Nov-2025",
            "statusDate": "18-Feb-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Dec-2020",
                "endDate": "18-Aug-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Aug-2024",
                "endDate": "28-Sep-2025",
                "successPercentage": "95%",
                "predictedDateL50": "27-Jan-2024",
                "predictedDateU50": "14-Dec-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Sep-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-May-2025",
                "predictedDateU50": "28-Nov-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "16-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, an implied trial approval was granted for allergic fungal sinusitis in China [ <ulink linkID=\"2369536\" linkType=\"Reference\">  2369536 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-May-2023",
                "milestoneExtendedDate": "31-May-2023",
                "notes": "In December 2020, a phase III trial (NCT04684524) for allergic fungal rhinosinusitis (AFRS) who previously have had surgery for AFRS was expected to complete in May 2023 [ <ulink linkID=\"2418345\" linkType=\"Reference\">  2418345 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3208",
              "name": "Nasal polyps"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "16-May-2023",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3615",
              "name": "Peanut hypersensitivity"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Oct-2018",
            "endDate": "22-Sep-2028",
            "statusDate": "15-Oct-2018",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "4.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Oct-2018",
                "endDate": "02-Feb-2025",
                "successPercentage": "55%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Feb-2025",
                "endDate": "25-Oct-2027",
                "successPercentage": "41%",
                "predictedDateL50": "13-Mar-2024",
                "predictedDateU50": "31-Aug-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Oct-2027",
                "endDate": "20-Aug-2028",
                "successPercentage": "94%",
                "predictedDateL50": "30-Aug-2026",
                "predictedDateU50": "31-Mar-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Aug-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-May-2028",
                "predictedDateU50": "22-Sep-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In February 2020, data from the phase II trial in peanut allergy were expected in 1H21 [ <ulink linkID=\"2247489\" linkType=\"Reference\">  2247489 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Mar-2021",
                "milestoneExtendedDate": "09-Mar-2021",
                "notes": "In September 2018, the phase II trial of dupilumab as adjunct to AR-101 for peanut allergy was expected to complete in March 2021 [ <ulink linkID=\"2076531\" linkType=\"Reference\">  2076531 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "3846",
              "name": "Prurigo nodularis"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Jan-2020",
            "endDate": "22-May-2025",
            "statusDate": "19-Mar-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "16-Jan-2020",
                "endDate": "13-Jun-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Jun-2024",
                "endDate": "13-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "20-Jan-2024",
                "predictedDateU50": "30-Sep-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Jan-2025",
                "predictedDateU50": "22-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Jul-2021",
                "notes": "In March 2020, the phase III trial (PRIME) assessing dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable was expected to complete in July 2021 in South Korea [ <ulink linkID=\"2247269\" linkType=\"Reference\">  2247269 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Oct-2021",
                "notes": "In September 2020, the phase III trial (PRIME) assessing dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable was expected to complete in October 2021 [ <ulink linkID=\"2247269\" linkType=\"Reference\">  2247269 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In January 2021, data from phase III trial of dupilumab in patients with prurigo nodularis were expected within 'the next 12-18 months' [ <ulink linkID=\"2391235\" linkType=\"Reference\"> 2391235 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "6187",
              "name": "Bullous pemphigoid"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": "Orphan Drug",
            "startDate": "",
            "endDate": "",
            "statusDate": "06-Feb-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19214",
              "name": "Regeneron Pharmaceuticals Inc"
            },
            "indication": {
              "id": "6187",
              "name": "Bullous pemphigoid"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": "1009547",
              "name": "Sanofi SA"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "06-Feb-2020",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "69095",
        "displayName": "capivasertib",
        "drugPrograms": [
          {
            "company": {
              "id": "1004334",
              "name": "Samsung Medical Center (SMC)"
            },
            "indication": {
              "id": "127",
              "name": "Stomach tumor"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Jan-2015",
            "endDate": "",
            "statusDate": "31-Jan-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "29-Jun-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "26%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "19-Jul-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Jul-2024",
                "endDate": "02-Aug-2026",
                "successPercentage": "50%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Aug-2026",
                "endDate": "27-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "13-Sep-2025",
                "predictedDateU50": "05-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Feb-2027",
                "predictedDateU50": "29-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "14-Sep-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "19%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "24-Jun-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jun-2024",
                "endDate": "17-Oct-2026",
                "successPercentage": "39%",
                "predictedDateL50": "31-Jan-2024",
                "predictedDateU50": "18-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Oct-2026",
                "endDate": "12-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Oct-2025",
                "predictedDateU50": "04-Mar-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Apr-2027",
                "predictedDateU50": "14-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "15-Nov-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "21%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "24-Jun-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jun-2024",
                "endDate": "17-Oct-2026",
                "successPercentage": "40%",
                "predictedDateL50": "31-Jan-2024",
                "predictedDateU50": "18-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Oct-2026",
                "endDate": "06-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Oct-2025",
                "predictedDateU50": "04-Mar-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Jun-2027",
                "predictedDateU50": "15-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jul-2021",
            "endDate": "30-Aug-2029",
            "statusDate": "26-Jul-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Jul-2021",
                "endDate": "04-May-2024",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "04-May-2024",
                "endDate": "04-May-2026",
                "successPercentage": "19%",
                "predictedDateL50": "02-Jan-2024",
                "predictedDateU50": "01-Aug-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "04-May-2026",
                "endDate": "04-Sep-2028",
                "successPercentage": "44%",
                "predictedDateL50": "27-Apr-2025",
                "predictedDateU50": "05-Oct-2026",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Sep-2028",
                "endDate": "20-Jul-2029",
                "successPercentage": "91%",
                "predictedDateL50": "05-Sep-2027",
                "predictedDateU50": "29-Jan-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jul-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "10-Apr-2029",
                "predictedDateU50": "30-Aug-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, a phase I trial (NCT04944771) for solid and hematological malignancies was expected to complete in January 2022 [ <ulink linkID=\"2487235\" linkType=\"Reference\">  2487235 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "799",
              "name": "Ovary tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2014",
            "endDate": "",
            "statusDate": "11-Nov-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Nov-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2015",
            "endDate": "",
            "statusDate": "31-Mar-2015",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "31-Mar-2015",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Dec-2010",
            "endDate": "",
            "statusDate": "11-Nov-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Dec-2010",
                "endDate": "11-Nov-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Nov-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "01-Jul-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "27%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "19-Jul-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Jul-2024",
                "endDate": "05-Aug-2026",
                "successPercentage": "52%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Aug-2026",
                "endDate": "30-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "16-Sep-2025",
                "predictedDateU50": "09-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2027",
                "predictedDateU50": "01-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "28-Oct-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "20%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "19-Jul-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Jul-2024",
                "endDate": "30-Nov-2026",
                "successPercentage": "42%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2026",
                "endDate": "24-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "21-Nov-2025",
                "predictedDateU50": "19-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jun-2027",
                "predictedDateU50": "28-Oct-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "04-Jan-2028",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "19-Jul-2024",
                "successPercentage": "54%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "19-Jul-2024",
                "endDate": "09-Dec-2026",
                "successPercentage": "47%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "06-Nov-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Dec-2026",
                "endDate": "24-Nov-2027",
                "successPercentage": "95%",
                "predictedDateL50": "27-Nov-2025",
                "predictedDateU50": "25-Apr-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "24-Nov-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-Jul-2027",
                "predictedDateU50": "04-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "23-Jun-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "30%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "11-Jul-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2024",
                "endDate": "25-Jul-2026",
                "successPercentage": "60%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "25-Oct-2024",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Jul-2026",
                "endDate": "21-May-2027",
                "successPercentage": "95%",
                "predictedDateL50": "05-Sep-2025",
                "predictedDateU50": "27-Nov-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Feb-2027",
                "predictedDateU50": "23-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "11-Sep-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "24%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "20-Jun-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2024",
                "endDate": "13-Oct-2026",
                "successPercentage": "49%",
                "predictedDateL50": "31-Jan-2024",
                "predictedDateU50": "10-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Oct-2026",
                "endDate": "09-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Oct-2025",
                "predictedDateU50": "28-Feb-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Apr-2027",
                "predictedDateU50": "11-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "13-Nov-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "25%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "20-Jun-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2024",
                "endDate": "13-Oct-2026",
                "successPercentage": "50%",
                "predictedDateL50": "31-Jan-2024",
                "predictedDateU50": "10-Sep-2024",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Oct-2026",
                "endDate": "05-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Oct-2025",
                "predictedDateU50": "28-Feb-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jun-2027",
                "predictedDateU50": "13-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "07-Jul-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "32%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "11-Jul-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2024",
                "endDate": "09-Aug-2026",
                "successPercentage": "64%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "25-Oct-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Aug-2026",
                "endDate": "03-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Sep-2025",
                "predictedDateU50": "13-Dec-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Feb-2027",
                "predictedDateU50": "07-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "10-Nov-2027",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "28%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "11-Jul-2024",
                "successPercentage": "51%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2024",
                "endDate": "13-Dec-2026",
                "successPercentage": "58%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "25-Oct-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-Dec-2026",
                "endDate": "07-Oct-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Nov-2025",
                "predictedDateU50": "30-Apr-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Jun-2027",
                "predictedDateU50": "10-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Nov-2021",
            "endDate": "18-Jan-2028",
            "statusDate": "03-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "31%",
            "timeToRegistration": "4.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Nov-2021",
                "endDate": "11-Jul-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Jul-2024",
                "endDate": "23-Dec-2026",
                "successPercentage": "62%",
                "predictedDateL50": "06-Feb-2024",
                "predictedDateU50": "25-Oct-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Dec-2026",
                "endDate": "08-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "29-Nov-2025",
                "predictedDateU50": "13-May-2027",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Aug-2027",
                "predictedDateU50": "18-Jan-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "24-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, a phase II trial (NCT05008055) was expected to complete in April 2023 in patients with r/r B-cell NHL and r/r FL, MZL, and MCL [2520642].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "02-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05008055; CAPITAL) in relapsed or refractory (R/R) B-cell Non-Hodgkin's lymphoma, R/R follicular lymphoma (FL), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL) was expected to complete in October 2023 [ <ulink linkID=\"2520642\" linkType=\"Reference\">  2520642 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2054",
              "name": "Hematological neoplasm"
            },
            "country": {
              "id": "EU",
              "name": "EU (DE)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "26-Jul-2021",
            "endDate": "17-Dec-2029",
            "statusDate": "26-Jul-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "5.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "26-Jul-2021",
                "endDate": "13-May-2024",
                "successPercentage": "78%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-May-2024",
                "endDate": "25-Jul-2026",
                "successPercentage": "24%",
                "predictedDateL50": "06-Jan-2024",
                "predictedDateU50": "20-Aug-2024",
                "phaseDuration": "2.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Jul-2026",
                "endDate": "14-Dec-2028",
                "successPercentage": "63%",
                "predictedDateL50": "13-Jun-2025",
                "predictedDateU50": "25-Dec-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Dec-2028",
                "endDate": "11-Nov-2029",
                "successPercentage": "95%",
                "predictedDateL50": "03-Dec-2027",
                "predictedDateU50": "03-May-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Nov-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Jul-2029",
                "predictedDateU50": "17-Dec-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "18-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, a phase I trial (NCT04944771) for solid and hematological malignancies was expected to complete in January 2022 [ <ulink linkID=\"2487235\" linkType=\"Reference\">  2487235 </ulink>]. </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "DE"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2243",
              "name": "Fallopian tube cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2014",
            "endDate": "",
            "statusDate": "11-Nov-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Nov-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "15-Sep-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "27-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "15-Dec-2025",
                "predictedDateU50": "24-Oct-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Mar-2027",
                "predictedDateU50": "15-Sep-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for adenocarcinoma was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "18-May-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "14-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Dec-2025",
                "predictedDateU50": "26-Oct-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jan-2027",
                "predictedDateU50": "18-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for adenocarcinoma was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Jul-2014",
            "endDate": "17-May-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Jul-2014",
                "endDate": "25-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "12-Apr-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jan-2026",
                "predictedDateU50": "21-Oct-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Apr-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "13-Jan-2027",
                "predictedDateU50": "17-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for adenocarcinoma was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "2399",
              "name": "Adenocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "28-Jul-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "70%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "20-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "19-Nov-2025",
                "predictedDateU50": "26-Oct-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "06-Mar-2027",
                "predictedDateU50": "28-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for adenocarcinoma was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3083",
              "name": "Peritoneal tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "11-Nov-2014",
            "endDate": "",
            "statusDate": "11-Nov-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "11-Nov-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2012",
            "endDate": "",
            "statusDate": "31-Jan-2014",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Nov-2012",
                "endDate": "31-Jan-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "31-Jan-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jul-2020",
            "endDate": "24-Jun-2025",
            "statusDate": "13-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Jul-2020",
                "endDate": "11-May-2024",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-May-2024",
                "endDate": "09-May-2025",
                "successPercentage": "95%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "30-Jul-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "07-Jan-2025",
                "predictedDateU50": "24-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "04-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, an implied clinical trial approval of the drug was obtained the drug in combination with abiraterone in patients with PTEN deficiency metastatic hormone dependent prostate cancer in China [<ulink linkType=\"Reference\" linkID=\"2312515\">2312515</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jul-2020",
            "endDate": "02-Mar-2025",
            "statusDate": "13-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Jul-2020",
                "endDate": "13-May-2024",
                "successPercentage": "61%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "13-May-2024",
                "endDate": "25-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "08-Jan-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Oct-2024",
                "predictedDateU50": "02-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT04493853; D361BC00001; CTR20202619) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2354707\" linkType=\"Reference\">  2354707 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jul-2020",
            "endDate": "19-Jan-2025",
            "statusDate": "13-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "57%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Jul-2020",
                "endDate": "02-Apr-2024",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Apr-2024",
                "endDate": "13-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "27-Dec-2023",
                "predictedDateU50": "25-May-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Sep-2024",
                "predictedDateU50": "19-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT04493853; D361BC00001; CTR20202619) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2354707\" linkType=\"Reference\">  2354707 </ulink>]</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3247",
              "name": "Hormone dependent prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "13-Jul-2020",
            "endDate": "18-Mar-2025",
            "statusDate": "13-Jul-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "53%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "13-Jul-2020",
                "endDate": "01-Jun-2024",
                "successPercentage": "56%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "01-Jun-2024",
                "endDate": "07-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Jan-2024",
                "predictedDateU50": "11-Sep-2024",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Nov-2024",
                "predictedDateU50": "18-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT04493853; D361BC00001; CTR20202619) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2354707\" linkType=\"Reference\">  2354707 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "09-Oct-2020",
            "endDate": "15-Feb-2025",
            "statusDate": "10-Oct-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "09-Oct-2020",
                "endDate": "10-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Oct-2023",
                "endDate": "05-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jul-2024",
                "predictedDateU50": "15-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT03997123; CapItello290) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [<ulink linkType=\"Reference\" linkID=\"2354707\">2354707</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "03-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In  December 2020, an implied trial approval was granted for capivasertib in combination with paclitaxel for the first-line treatment of advanced or metastatic triple negative breast cancer in China [<ulink linkType=\"Reference\" linkID=\"2369536\">2369536</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "29-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, an implied trial approval was granted for breast cancer in China [ <ulink linkID=\"2485826\" linkType=\"Reference\">  2485826 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "30-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In August 2021, an implied trial was granted for or capivasertib in combination with paclitaxel for the first-line treatment of advanced or metastatic triple negative breast cancer in China [ <ulink linkID=\"2502642\" linkType=\"Reference\">  2502642 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "28-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, an implied trial approval was granted for triple negative breast cancer in China [ <ulink linkID=\"2591285\" linkType=\"Reference\">  2591285 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive clinical data from phase III trial (NCT04305496) in metastatic breast cancer demonstrating good efficacy in increasing median time to 7.2 months and decreasing tumor volume were reported [  <ulink linkID=\"2784201\" linkType=\"Reference\">  2784201 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2022, data from the phase III CAPItello-291 trial (NCT04305496) for locally advanced or metastatic HR+/HER2− breast cancer following recurrence or progression on or after aromatase inhibitor therapy were expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03997123; CapItello290) were expected in 2H23 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "10-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, an NDA was filed in China [ <ulink linkID=\"3374894\" linkType=\"Reference\"> 3374894 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Dec-2010",
            "endDate": "10-Nov-2024",
            "statusDate": "10-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Dec-2010",
                "endDate": "03-Oct-2012",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "03-Oct-2012",
                "endDate": "10-Dec-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "07-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "22-May-2023",
                "predictedDateU50": "07-Mar-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jun-2024",
                "predictedDateU50": "10-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2018, AstraZeneca expected to complete a phase II trial in metastatic breast cancer in March 2019 [<ulink linkType=\"Reference\" linkID=\"1432848\">1432848</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT03997123; CapItello290) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [<ulink linkType=\"Reference\" linkID=\"2354707\">2354707</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive clinical data from phase III trial (NCT04305496) in metastatic breast cancer demonstrating good efficacy in increasing median time to 7.2 months and decreasing tumor volume were reported [  <ulink linkID=\"2784201\" linkType=\"Reference\">  2784201 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2022, data from the phase III CAPItello-291 trial (NCT04305496) for locally advanced or metastatic HR+/HER2− breast cancer following recurrence or progression on or after aromatase inhibitor therapy were expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03997123; CapItello290) were expected in 2H23 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "12-Jul-2024",
                "milestoneExtendedDate": "",
                "notes": "In March 2020, a phase III trial (NCT04305496; CAPItello-291) in patients with locally advanced or metastatic HR+/HER2− breast cancer was expected to complete in July 2024 [<ulink linkType=\"Reference\" linkID=\"2255165\">2255165</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-Oct-2012",
            "endDate": "",
            "statusDate": "03-Oct-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "03-Oct-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Dec-2010",
            "endDate": "",
            "statusDate": "03-Oct-2012",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Dec-2010",
                "endDate": "03-Oct-2012",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "03-Oct-2012",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Priority Review",
            "startDate": "01-Dec-2010",
            "endDate": "10-May-2024",
            "statusDate": "12-Jun-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Dec-2010",
                "endDate": "11-Nov-2014",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "11-Nov-2014",
                "endDate": "16-Apr-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Apr-2020",
                "endDate": "12-Jun-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jun-2023",
                "endDate": "09-Apr-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "25-Jan-2024",
                "predictedDateU50": "10-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT03997123; CapItello290) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [<ulink linkType=\"Reference\" linkID=\"2354707\">2354707</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive clinical data from phase III trial (NCT04305496) in metastatic breast cancer demonstrating good efficacy in increasing median time to 7.2 months and decreasing tumor volume were reported [  <ulink linkID=\"2784201\" linkType=\"Reference\">  2784201 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2022, data from the phase III CAPItello-291 trial (NCT04305496) for locally advanced or metastatic HR+/HER2− breast cancer following recurrence or progression on or after aromatase inhibitor therapy were expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "09-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "By February 2023, Fast Track designations to capivasertib was granted by the US FDA for the treatment of first-line HR-positive HER2-negative breast cancer [ <ulink linkID=\"2820841\" linkType=\"Reference\">  2820841 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "12-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, the FDA accepted an NDA for Priority Review for the drug in combination with fulvestrant, for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer [ <ulink linkID=\"2972364\" linkType=\"Reference\"> 2972364 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "12-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In June 2023, an NDA for capivasertib in combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer had been accepted [ <ulink linkID=\"2972364\" linkType=\"Reference\"> 2972364 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03997123; CapItello290) were expected in 2H23 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In June 2023, the US FDA accepted the NDA for capivasertib in combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer, with a Prescription Drug User Fee Act date set in 4Q23 [ <ulink linkID=\"2972364\" linkType=\"Reference\"> 2972364 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Dec-2010",
            "endDate": "05-Feb-2025",
            "statusDate": "25-Jun-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Dec-2010",
                "endDate": "03-Oct-2012",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "03-Oct-2012",
                "endDate": "25-Jun-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Jun-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "17-Dec-2024",
                "successPercentage": "95%",
                "predictedDateL50": "30-Apr-2023",
                "predictedDateU50": "11-Mar-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Aug-2024",
                "predictedDateU50": "05-Feb-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Mar-2019",
                "milestoneExtendedDate": "",
                "notes": "In March 2018, AstraZeneca expected to complete a phase II trial in metastatic breast cancer in March 2019 [<ulink linkType=\"Reference\" linkID=\"1432848\">1432848</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "01-Nov-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2020, data from a phase III trial (NCT03997123; CapItello290) were expected in 2021 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [<ulink linkType=\"Reference\" linkID=\"2354707\">2354707</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive clinical data from phase III trial (NCT04305496) in metastatic breast cancer demonstrating good efficacy in increasing median time to 7.2 months and decreasing tumor volume were reported [  <ulink linkID=\"2784201\" linkType=\"Reference\">  2784201 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2022",
                "milestoneExtendedDate": "31-Dec-2022",
                "notes": "In July 2022, data from the phase III CAPItello-291 trial (NCT04305496) for locally advanced or metastatic HR+/HER2− breast cancer following recurrence or progression on or after aromatase inhibitor therapy were expected in 2H22 [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "26-Oct-2022",
                "milestoneExtendedDate": "",
                "notes": "In October 2022, topline data from the phase III Capitello-291 (NCT04305496) study in locally advanced or metastatic HR+/HER2- breast were reported demonstrating the trial met its primary endpoint, with a significant improvement in progression-free survival observed for patients who received capivasertib + fulvestrant versus placebo + fulvestrant in both the overall patient population and in a prespecified biomarker subgroup which included patients with PIK3CA, AKT1 and PTEN gene mutations [ <ulink linkID=\"2759240\" linkType=\"Reference\">  2759240 </ulink>]. [ <ulink linkID=\"2758882\" linkType=\"Reference\">  2758882 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In July 2022, data from a phase III trial (NCT03997123; CapItello290) were expected in 2H23 in patients with locally advanced (inoperable) or metastatic triple negative breast cancer [ <ulink linkID=\"2710957\" linkType=\"Reference\">  2710957 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "17-Jul-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, a phase III trial (NCT04305496; CAPItello-291) was expected to complete in July 2024 in patients with locally advanced or metastatic HR+/HER2− breast cancer [<ulink linkType=\"Reference\" linkID=\"2255165\">2255165</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "29-Aug-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "66%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "18-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "20-Dec-2025",
                "predictedDateU50": "29-Oct-2026",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Mar-2027",
                "predictedDateU50": "29-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for metastatic prostate cancer was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "08-May-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "70%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "30-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "26-Dec-2025",
                "predictedDateU50": "27-Oct-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Jan-2027",
                "predictedDateU50": "08-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for metastatic prostate cancer was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "25-Mar-2022",
            "endDate": "05-May-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "67%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "71%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "27-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Jan-2026",
                "predictedDateU50": "21-Oct-2026",
                "phaseDuration": "0.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jan-2027",
                "predictedDateU50": "05-May-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for metastatic prostate cancer was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "14190",
              "name": "AstraZeneca PLC"
            },
            "indication": {
              "id": "3664",
              "name": "Metastatic prostate cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Feb-2021",
            "endDate": "20-Jul-2027",
            "statusDate": "25-Mar-2022",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "61%",
            "timeToRegistration": "3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Feb-2021",
                "endDate": "25-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Mar-2022",
                "endDate": "22-Jul-2026",
                "successPercentage": "64%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Jul-2026",
                "endDate": "11-Jun-2027",
                "successPercentage": "95%",
                "predictedDateL50": "10-Dec-2025",
                "predictedDateU50": "26-Oct-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jun-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Mar-2027",
                "predictedDateU50": "20-Jul-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Jul-2026",
                "milestoneExtendedDate": "",
                "notes": "In December 2022, a phase III trial (NCT05348577; CAPItello-280) for metastatic prostate cancer was expected to complete in July 2026 [ <ulink linkID=\"2675148\" linkType=\"Reference\">  2675148 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "72635",
        "displayName": "ivosidenib",
        "drugPrograms": [
          {
            "company": {
              "id": "1040627",
              "name": "Agios Pharmaceuticals Inc"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "US",
              "name": "US, US, US"
            },
            "principalCompany": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "25-Aug-2021",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1126254",
              "name": "CStone Pharmaceuticals"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Nov-2020",
            "endDate": "",
            "statusDate": "10-Nov-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "10-Nov-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "06-Mar-2028",
            "statusDate": "14-Apr-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "45%",
            "timeToRegistration": "4.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "14-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "14-Apr-2021",
                "endDate": "02-Aug-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Aug-2024",
                "endDate": "09-Apr-2027",
                "successPercentage": "76%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "12-Dec-2024",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Apr-2027",
                "endDate": "02-Feb-2028",
                "successPercentage": "79%",
                "predictedDateL50": "17-Feb-2026",
                "predictedDateU50": "10-Sep-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Feb-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Oct-2027",
                "predictedDateU50": "06-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR, NL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2014",
            "endDate": "01-Mar-2026",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "58%",
            "timeToRegistration": "2.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2014",
                "endDate": "01-Mar-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.11",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Mar-2019",
                "endDate": "29-Jan-2025",
                "successPercentage": "79%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "29-Jan-2025",
                "endDate": "19-Jan-2026",
                "successPercentage": "73%",
                "predictedDateL50": "12-Aug-2024",
                "predictedDateU50": "03-May-2025",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jan-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Sep-2025",
                "predictedDateU50": "01-Mar-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR",
              " NL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1272",
              "name": "Myelodysplastic syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2014",
            "endDate": "",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB, IS, LI, NO)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "31-Mar-2014",
            "endDate": "",
            "statusDate": "10-Mar-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "31-Mar-2014",
                "endDate": "20-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2017",
                "endDate": "31-Dec-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "31-Dec-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU",
              " GB",
              " IS",
              " LI",
              " NO"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Jun-2017",
            "endDate": "07-Dec-2024",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "26-Oct-2024",
                "successPercentage": "94%",
                "predictedDateL50": "15-Mar-2023",
                "predictedDateU50": "09-Apr-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jul-2024",
                "predictedDateU50": "07-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "13-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, positive topline data from a phase III trial (NCT03173248; AGILE) of ivosidenib in patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation were presented. In patients treated with ivosidenib + azacytidine (n = 72) versus placebo + azacytidine (n = 74) in intent-to-treat population, hazard ratio (HR) for event-free survival (EFS; primary endpoint) was 0.33 (one-sided p = 0.0011). Median EFS was not reached in ivosidenib + azacytidine-treated patients who achieved complete remission (CR) by 24 weeks but with placebo + azacytidine was 17.8 months. Median overall survival (OS) was 24.0 versus 7.9 months (HR: 0.44; one-sided p = 0.0005) with ivosidenib + azacytidine versus placebo + azacytidine [ <ulink linkID=\"2582471\" linkType=\"Reference\">  2582471 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, positive topline data from a phase III trial (NCT03173248; AGILE) of ivosidenib in patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation were presented. In patients treated with ivosidenib + azacytidine (n = 72) versus placebo + azacytidine (n = 74) in intent-to-treat population, hazard ratio (HR) for event-free survival (EFS; primary endpoint) was 0.33 (one-sided p = 0.0011). Median EFS was not reached in ivosidenib + azacytidine-treated patients who achieved complete remission (CR) by 24 weeks but with placebo + azacytidine was 17.8 months. Median overall survival (OS) was 24.0 versus 7.9 months (HR: 0.44; one-sided p = 0.0005) with ivosidenib + azacytidine versus placebo + azacytidine [ <ulink linkID=\"2582471\" linkType=\"Reference\">  2582471 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1731",
              "name": "Acute myelogenous leukemia"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Jun-2017",
            "endDate": "05-Dec-2024",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "22-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "16-Jun-2023",
                "predictedDateU50": "11-May-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Jul-2024",
                "predictedDateU50": "05-Dec-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "13-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, positive topline data from a phase III trial (NCT03173248; AGILE) of ivosidenib in patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation were presented. In patients treated with ivosidenib + azacytidine (n = 72) versus placebo + azacytidine (n = 74) in intent-to-treat population, hazard ratio (HR) for event-free survival (EFS; primary endpoint) was 0.33 (one-sided p = 0.0011). Median EFS was not reached in ivosidenib + azacytidine-treated patients who achieved complete remission (CR) by 24 weeks but with placebo + azacytidine was 17.8 months. Median overall survival (OS) was 24.0 versus 7.9 months (HR: 0.44; one-sided p = 0.0005) with ivosidenib + azacytidine versus placebo + azacytidine [ <ulink linkID=\"2582471\" linkType=\"Reference\">  2582471 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "13-Dec-2021",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, positive topline data from a phase III trial (NCT03173248; AGILE) of ivosidenib in patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation were presented. In patients treated with ivosidenib + azacytidine (n = 72) versus placebo + azacytidine (n = 74) in intent-to-treat population, hazard ratio (HR) for event-free survival (EFS; primary endpoint) was 0.33 (one-sided p = 0.0011). Median EFS was not reached in ivosidenib + azacytidine-treated patients who achieved complete remission (CR) by 24 weeks but with placebo + azacytidine was 17.8 months. Median overall survival (OS) was 24.0 versus 7.9 months (HR: 0.44; one-sided p = 0.0005) with ivosidenib + azacytidine versus placebo + azacytidine [ <ulink linkID=\"2582471\" linkType=\"Reference\">  2582471 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (EU, GB, IS, LI, NO)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "07-Mar-2024",
            "statusDate": "10-Mar-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "11-Dec-2016",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "11-Dec-2016",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Mar-2022",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Dec-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Sep-2023",
                "predictedDateU50": "07-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "10-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In March 2022, MAA was submitted to EMA for TIBSOVO in combination with azacitidine, in patients with previously untreated IDH1-mutated acute myeloid leukemia (AML) and not eligible for intensive chemotherapy, as well as in previously treated, locally advanced or metastatic IDH1-mutated cholangiocarcinoma [  <ulink linkID=\"2630244\" linkType=\"Reference\">  2630244  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "24-Feb-2023",
                "milestoneExtendedDate": "",
                "notes": "In February 2023, CHMP of the EMA adopted a positive opinion and recommended granting a marketing authorization for ivosidenib for the treatment of advanced or metastatic IDH1-mutated cholangiocarcinoma, previously treated by at least one prior line of systemic therapy [ <ulink linkID=\"2833730\" linkType=\"Reference\">  2833730 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU",
              " GB",
              " IS",
              " LI",
              " NO"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "1765",
              "name": "Cholangiocarcinoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Apr-2021",
            "endDate": "13-May-2025",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "01-Apr-2021",
                "endDate": "11-May-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "11-May-2024",
                "endDate": "04-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "10-Jan-2024",
                "predictedDateU50": "11-Aug-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Dec-2024",
                "predictedDateU50": "13-May-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "2444",
              "name": "Chondrosarcoma"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "11-Jun-2032",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "11%",
            "timeToRegistration": "8.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "10-Nov-2025",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "11.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Nov-2025",
                "endDate": "31-Jul-2028",
                "successPercentage": "27%",
                "predictedDateL50": "18-Apr-2024",
                "predictedDateU50": "23-Nov-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Jul-2028",
                "endDate": "30-Apr-2031",
                "successPercentage": "53%",
                "predictedDateL50": "03-May-2027",
                "predictedDateU50": "09-Mar-2029",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Apr-2031",
                "endDate": "27-Apr-2032",
                "successPercentage": "88%",
                "predictedDateL50": "04-Mar-2030",
                "predictedDateU50": "13-Oct-2031",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Apr-2032",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Dec-2031",
                "predictedDateU50": "11-Jun-2032",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "2444",
              "name": "Chondrosarcoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (FR)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "FR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "3713",
              "name": "Advanced solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "01-Mar-2014",
            "endDate": "23-Feb-2028",
            "statusDate": "14-Apr-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "18%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "01-Mar-2014",
                "endDate": "14-Apr-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "14-Apr-2021",
                "endDate": "02-Aug-2024",
                "successPercentage": "42%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Aug-2024",
                "endDate": "14-Mar-2027",
                "successPercentage": "61%",
                "predictedDateL50": "23-Jan-2024",
                "predictedDateU50": "12-Dec-2024",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Mar-2027",
                "endDate": "12-Jan-2028",
                "successPercentage": "70%",
                "predictedDateL50": "25-Jan-2026",
                "predictedDateU50": "04-Aug-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Jan-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Oct-2027",
                "predictedDateU50": "23-Feb-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19863",
              "name": "Les Laboratories Servier SAS"
            },
            "indication": {
              "id": "6833",
              "name": "Chronic myelomonocytic leukemia"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "16-Jan-2019",
            "endDate": "19-Mar-2031",
            "statusDate": "01-Apr-2021",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "12%",
            "timeToRegistration": "7.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "16-Jan-2019",
                "endDate": "23-Oct-2024",
                "successPercentage": "87%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "23-Oct-2024",
                "endDate": "13-Jul-2027",
                "successPercentage": "25%",
                "predictedDateL50": "07-Feb-2024",
                "predictedDateU50": "08-May-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Jul-2027",
                "endDate": "03-Apr-2030",
                "successPercentage": "60%",
                "predictedDateL50": "04-Apr-2026",
                "predictedDateU50": "07-Mar-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Apr-2030",
                "endDate": "02-Feb-2031",
                "successPercentage": "90%",
                "predictedDateL50": "06-Feb-2029",
                "predictedDateU50": "08-Sep-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Feb-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Oct-2030",
                "predictedDateU50": "19-Mar-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "73249",
        "displayName": "tovorafenib",
        "drugPrograms": [
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Jul-2021",
            "endDate": "04-May-2028",
            "statusDate": "22-Nov-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "15-Jul-2021",
                "endDate": "29-Sep-2024",
                "successPercentage": "7%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "06-Jun-2027",
                "successPercentage": "47%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "04-Apr-2025",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jun-2027",
                "endDate": "01-Apr-2028",
                "successPercentage": "82%",
                "predictedDateL50": "18-Apr-2026",
                "predictedDateU50": "12-Nov-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2027",
                "predictedDateU50": "04-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, initial data from a phase I/II trial (NCT04985604, FIRELIGHT-1) for the treatment of melanoma and solid tumors were presented [ <ulink linkID=\"2917430\" linkType=\"Reference\"> 2917430 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial termination",
                "status": "Negative Outcome",
                "milestoneDate": "30-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, phase IIa FIRELIGHT-1 monotherapy substudy trial was planned to discontinue y as a limited duration of response were observed [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In November 2021 a phase I/II trial (NCT04985604) was expected to be completed by December 2025 [ <ulink linkID=\"2583287\" linkType=\"Reference\">  2583287 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "15-Sep-2011",
            "endDate": "28-May-2028",
            "statusDate": "10-Aug-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "4.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "15-Sep-2011",
                "endDate": "12-Jan-2015",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "12-Jan-2015",
                "endDate": "29-Sep-2024",
                "successPercentage": "7%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "9.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "29-Sep-2024",
                "endDate": "02-Jul-2027",
                "successPercentage": "53%",
                "predictedDateL50": "04-Jan-2024",
                "predictedDateU50": "04-Apr-2025",
                "phaseDuration": "2.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "02-Jul-2027",
                "endDate": "25-Apr-2028",
                "successPercentage": "88%",
                "predictedDateL50": "04-May-2026",
                "predictedDateU50": "20-Dec-2027",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Apr-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jan-2028",
                "predictedDateU50": "28-May-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "31-Mar-2022",
                "notes": "In November 2021, phase Ib combination portion of the study with oral MEK inhibitor, pimasertib was expected to begin in the first quarter of 2022 [ <ulink linkID=\"2571344\" linkType=\"Reference\">  2571344 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "20-Apr-2023",
                "milestoneExtendedDate": "",
                "notes": "In April 2023, initial data from a phase I/II trial (NCT04985604, FIRELIGHT-1) for the treatment of melanoma and solid tumors were presented [ <ulink linkID=\"2917430\" linkType=\"Reference\"> 2917430 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial termination",
                "status": "Negative Outcome",
                "milestoneDate": "30-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, phase IIa FIRELIGHT-1 monotherapy substudy trial was planned to discontinue y as a limited duration of response were observed [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Dec-2025",
                "milestoneExtendedDate": "",
                "notes": "In November 2021 a phase I/II trial (NCT04985604) was expected to be completed by December 2025 [ <ulink linkID=\"2583287\" linkType=\"Reference\">  2583287 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Apr-2021",
            "endDate": "20-Mar-2027",
            "statusDate": "18-Jan-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "79%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Apr-2021",
                "endDate": "27-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2023",
                "endDate": "21-Apr-2026",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Apr-2026",
                "endDate": "15-Feb-2027",
                "successPercentage": "92%",
                "predictedDateL50": "04-May-2025",
                "predictedDateU50": "07-Sep-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Oct-2026",
                "predictedDateU50": "20-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In August 2021, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in the first half of 2022 [ <ulink linkID=\"2509077\" linkType=\"Reference\">  2509077 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In March 2022, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in June 2022 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In March 2022, topline data from phase II trial (NCT04775485; FIREFLY-1) were expected in first quarter of 2023 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline results from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were reported [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In January 2023, additional data from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were expected in the second quarter of 2023 [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, data from phase II trial (NCT04775485; FIREFLY-1) were reported [ <ulink linkID=\"3159810\" linkType=\"Reference\"> 3159810 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "17-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, data from phase II (NCT04775485: FIREFLY-1) trial were planned to present in November 2023 [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "Singapore",
              "name": "Singapore"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Apr-2021",
            "endDate": "17-Nov-2027",
            "statusDate": "18-Jan-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "76%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Apr-2021",
                "endDate": "27-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2023",
                "endDate": "27-Oct-2026",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "27-Oct-2026",
                "endDate": "08-Oct-2027",
                "successPercentage": "91%",
                "predictedDateL50": "16-Sep-2025",
                "predictedDateU50": "13-Apr-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jun-2027",
                "predictedDateU50": "17-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In March 2022, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in June 2022 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In March 2022, topline data from phase II trial (NCT04775485; FIREFLY-1) were expected in first quarter of 2023 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline results from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were reported [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In January 2023, additional data from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were expected in the second quarter of 2023 [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, data from phase II trial (NCT04775485; FIREFLY-1) were reported [ <ulink linkID=\"3159810\" linkType=\"Reference\"> 3159810 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "17-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, data from phase II (NCT04775485: FIREFLY-1) trial were planned to present in November 2023 [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "SG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Rare Pediatric Disease, Priority Review",
            "startDate": "25-Jun-2018",
            "endDate": "22-Jun-2024",
            "statusDate": "30-Oct-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "93%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "25-Jun-2018",
                "endDate": "27-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2023",
                "endDate": "30-Oct-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Oct-2023",
                "endDate": "14-May-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-May-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Feb-2024",
                "predictedDateU50": "22-Jun-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "24-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, the FDA had granted DAY-101 Orphan Drug designation for the treatment of malignant glioma [  <ulink linkID=\"2404849\" linkType=\"Reference\">  </ulink> <ulink linkID=\"2502782\" linkType=\"Reference\">  2502782  </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Rare Pediatric Disease",
                "status": "Granted",
                "milestoneDate": "27-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In July 2021, the US FDA granted Rare Pediatric Disease Designation for the treatment of low-grade gliomas harboring an activating RAF alteration that disproportionately affects children [ <ulink linkID=\"2499890\" linkType=\"Reference\">  2499890 </ulink> ]</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In August 2021, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in the first half of 2022 [ <ulink linkID=\"2509077\" linkType=\"Reference\">  2509077 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In March 2022, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in June 2022 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In March 2022, topline data from phase II trial (NCT04775485; FIREFLY-1) were expected in first quarter of 2023 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline results from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were reported [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In January 2023, additional data from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were expected in the second quarter of 2023 [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In April 2023, NDA submission for tovorafenib for the treatment relapsed or progressive pLGG, was expected in 2Q23 [ <ulink linkID=\"2917430\" linkType=\"Reference\"> 2917430 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, data from phase II trial (NCT04775485; FIREFLY-1) were reported [ <ulink linkID=\"3159810\" linkType=\"Reference\"> 3159810 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Month)",
                "milestoneDate": "01-Oct-2023",
                "milestoneExtendedDate": "31-Oct-2023",
                "notes": "In August 2023, the NDA for tovorafenib, for the treatment of relapsed or progressive pLGG, was expected to be submitted by October 2023 [ <ulink linkID=\"3035469\" linkType=\"Reference\"> 3035469 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Priority Review",
                "status": "Granted",
                "milestoneDate": "30-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, NDA was accepted by US FDA and priority review was granted for tovorafenib in relapsed or progressive pediatric low-grade glioma [ <ulink linkID=\"3483373\" linkType=\"Reference\"> 3483373 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "11-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, NDA submission for tovorafenib for the treatment of relapsed or progressive pediatric low-grade glioma was completed [ <ulink linkID=\"3159810\" linkType=\"Reference\"> 3159810 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "17-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, data from phase II (NCT04775485: FIREFLY-1) trial were planned to present in November 2023 [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "28-Feb-2024",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, phase II trial of DAY-101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma harboring a known BRAF alteration was planned to complete in February 2024 [ <ulink linkID=\"2459371\" linkType=\"Reference\">  2459371 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "30-Apr-2024",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the prescription drug user fee act target action date for tovorafenib in relapsed or progressive pediatric low-grade glioma was set as April 30, 2024 [ <ulink linkID=\"3483373\" linkType=\"Reference\"> 3483373 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "1108",
              "name": "Glioma"
            },
            "country": {
              "id": "EU",
              "name": "Europe(X5)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "22-Apr-2021",
            "endDate": "23-Nov-2027",
            "statusDate": "18-Jan-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "77%",
            "timeToRegistration": "3.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Apr-2021",
                "endDate": "27-Feb-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.8",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "27-Feb-2023",
                "endDate": "04-Nov-2026",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Nov-2026",
                "endDate": "13-Oct-2027",
                "successPercentage": "86%",
                "predictedDateL50": "24-Sep-2025",
                "predictedDateU50": "22-Apr-2027",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "13-Oct-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jun-2027",
                "predictedDateU50": "23-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "21-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, the European Commission granted  Orphan Drug designation to DAY-101, based on the positive opinion from the European Medicines Agency (EMA) Committee for the treatment of glioma [ <ulink linkID=\"2479698\" linkType=\"Reference\">  2479698 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Month)",
                "milestoneDate": "01-Jun-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In March 2022, the initial data from phase II trial (NCT04775485; FIREFLY-1) were expected in June 2022 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Mar-2023",
                "notes": "In March 2022, topline data from phase II trial (NCT04775485; FIREFLY-1) were expected in first quarter of 2023 [ <ulink linkID=\"2627383\" linkType=\"Reference\">  2627383 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Jan-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, positive topline results from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were reported [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2023",
                "milestoneExtendedDate": "30-Jun-2023",
                "notes": "In January 2023, additional data from phase II study (NCT04775485) in patients with recurrent or progressive pediatric low-grade glioma were expected in the second quarter of 2023 [ <ulink linkID=\"2804468\" linkType=\"Reference\">  2804468 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-Jun-2023",
                "milestoneExtendedDate": "",
                "notes": "In September 2023, data from phase II trial (NCT04775485; FIREFLY-1) were reported [ <ulink linkID=\"3159810\" linkType=\"Reference\"> 3159810 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "17-Nov-2023",
                "milestoneExtendedDate": "",
                "notes": "By September 2023, data from phase II (NCT04775485: FIREFLY-1) trial were planned to present in November 2023 [ <ulink linkID=\"3491491\" linkType=\"Reference\"> 3491491 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5",
              " X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1227462",
              "name": "Day One Biopharmaceuticals Inc"
            },
            "indication": {
              "id": "4682",
              "name": "Histiocytosis"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Jul-2023",
            "endDate": "29-Oct-2029",
            "statusDate": "14-Jul-2023",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "42%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "14-Jul-2023",
                "endDate": "23-Feb-2026",
                "successPercentage": "60%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "23-Feb-2026",
                "endDate": "07-Nov-2028",
                "successPercentage": "76%",
                "predictedDateL50": "19-Nov-2024",
                "predictedDateU50": "07-Sep-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Nov-2028",
                "endDate": "17-Sep-2029",
                "successPercentage": "92%",
                "predictedDateL50": "20-Sep-2027",
                "predictedDateU50": "17-Apr-2029",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Jun-2029",
                "predictedDateU50": "29-Oct-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "77343",
        "displayName": "zanubrutinib",
        "drugPrograms": [
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "316",
              "name": "B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "",
            "statusDate": "22-Mar-2017",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-0.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "11-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jul-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "316",
              "name": "B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "",
            "statusDate": "07-Oct-2016",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-0.9",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "19-Jan-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "8.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "19-Jan-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "316",
              "name": "B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "",
            "statusDate": "20-Feb-2020",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2016",
            "endDate": "",
            "statusDate": "04-Jan-2018",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "-3.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "29-Jun-2016",
                "endDate": "04-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "04-Jan-2018",
                "endDate": "15-Jun-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Jun-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1743",
              "name": "Lymphoplasmacytic lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB, GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "04-Sep-2014",
            "endDate": "23-Nov-2021",
            "statusDate": "15-Dec-2021",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "-2.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "25-Jan-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Jan-2017",
                "endDate": "18-Jun-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "18-Jun-2020",
                "endDate": "23-Nov-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Nov-2021",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2019",
                "milestoneExtendedDate": "31-Dec-2019",
                "notes": "In February 2019, top-line data from a phase III study for WM were expected in 2019 [ <ulink linkID=\"2124059\" linkType=\"Reference\"> 2124059 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Positive Opinion",
                "milestoneDate": "17-Apr-2019",
                "milestoneExtendedDate": "",
                "notes": "In April 2019, the COMP recommended granting Orphan designation to zanubrutinib for treatment of lymphoplasmacytic lymphoma [ <ulink linkID=\"2151157\" linkType=\"Reference\"> 2151157 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Orphan Drug",
                "status": "Granted",
                "milestoneDate": "29-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, the Orphan designation was granted [ <ulink linkID=\"2169515\" linkType=\"Reference\"> 2169515 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "14-Jun-2019",
                "milestoneExtendedDate": "",
                "notes": "In June 2019, phase III results from an exploratory cohort of patients with lymphoplasmacytic lymphoma were presented [ <ulink linkID=\"2164600\" linkType=\"Reference\"> 2164600 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "16-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, the primary endpoint of statistical superiority related to deep response (VGPR or Better) was not met [ <ulink linkID=\"2228892\" linkType=\"Reference\"> 2228892 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Dec-2019",
                "milestoneExtendedDate": "",
                "notes": "In December 2019, results from the trial were reported [ <ulink linkID=\"2228892\" linkType=\"Reference\"> 2228892 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "18-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, the EMA accepted a marketing authorization application (MAA) for zanubrutinib for the treatment of patients with WM who have received at least one prior therapy or as first-line treatment for patients unsuitable for chemo-immunotherapy [ <ulink linkID=\"2291415\" linkType=\"Reference\"> 2291415 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Outcome",
                "milestoneDate": "16-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, the CHMP adopted a positive opinion, recommending the granting of a marketing authorisation for Brukinsa, intended for the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy [ <ulink linkID=\"2535359\" linkType=\"Reference\"> 2535359 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "By September 2021, the MHRA had accepted the MAA for BRUKINSA, in the UK for patients with WM [ <ulink linkID=\"2561042\" linkType=\"Reference\"> 2561042 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2021, EMA approval for treating adult patients with WM who have received at least one prior therapy or first-line treatment for patients unsuitable for chemo-immunotherapy was expected in 2021 [ <ulink linkID=\"2561042\" linkType=\"Reference\"> 2561042 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB",
              " GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "21-Aug-2019",
            "endDate": "16-Aug-2027",
            "statusDate": "21-Aug-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "3.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "21-Aug-2019",
                "endDate": "16-Aug-2026",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Aug-2026",
                "endDate": "06-Jul-2027",
                "successPercentage": "95%",
                "predictedDateL50": "14-Mar-2026",
                "predictedDateU50": "30-Nov-2026",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Jul-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Mar-2027",
                "predictedDateU50": "16-Aug-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2026",
                "milestoneExtendedDate": "31-Aug-2026",
                "notes": "In May 2020, a phase III study (NCT04002297) was expected to complete in August 2026 in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation [ <ulink linkID=\"2284203\" linkType=\"Reference\"> 2284203 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1744",
              "name": "Mantle cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "28-Nov-2027",
            "statusDate": "21-Aug-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "3.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "21-Aug-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Aug-2019",
                "endDate": "16-Aug-2026",
                "successPercentage": "88%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Aug-2026",
                "endDate": "28-Sep-2027",
                "successPercentage": "95%",
                "predictedDateL50": "09-Feb-2026",
                "predictedDateU50": "11-Dec-2026",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Sep-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-May-2027",
                "predictedDateU50": "28-Nov-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "10-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, further positive data from a phase I study (NCT04277637) in patients with B-cell malignancies were presented. At the data cut-off (February 2022), a total of 78 patients received treatment in BGB-11417 (40, 80, 160, 320 or 640 mg, qd, po) monotherapy (n = 26 relapsed or refractory NHL, cohort 1A; n = 6 R/R CLL/SLL, cohort 1B; n = 2 R/R WM cohort 1E) and BGB-11417 + zanubrutinib (320 mg, qd) combination cohorts (n = 20 R/R CLL/SLL, cohort 3A; n = 10 R/R MCL, cohort 3B; n = 14 treatment-naive CLL/SLL, cohort 4B). In cohort 1A, the dose-escalation was completed with no MTD reached through 640 mg dose and one DLT observed at 160 mg (grade 3 febrile neutropenia). For monotherapy cohorts 1B and 1C, dose escalation was continued; one DLT (grade 4 neutropenia) was observed in cohort 1B (R/R CLL) at 80 mg (patient recovered and continued dosing). For all combination cohorts, dose escalation was continued and no DLT was noted up to 160 (CLL) or 80 mg (MCL). Grade &gt;/= 3 treatment-emergent AEs (TEAEs) reported in the monotherapy cohorts were neutropenia (12.6%); fall, thrombocytopenia and abdominal pain (each 5.9%); pyrexia, arthralgia, increased AST and back pain (each 3.0%). Grade &gt;/= 3 TEAEs reported in the combination cohorts were neutropenia (6.9%), COVID-19 (2.2%) and anemia (2.2%). In one CLL patient with high baseline tumor lysis syndrome (TLS) risk receiving monotherapy, a marked tumor flare was observed on drug withdrawal; laboratory TLS in a late ramp-up (80 mg) was observed, with no sequelae, that was resolved by the next day and the drug was not withheld [ <ulink linkID=\"2740292\" linkType=\"Reference\"> 2740292 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2026",
                "milestoneExtendedDate": "31-Aug-2026",
                "notes": "In May 2020, a phase III study (NCT04002297) was expected to complete in August 2026 in patients with previously untreated mantle cell lymphoma who are ineligible for stem cell transplantation [ <ulink linkID=\"2284203\" linkType=\"Reference\"> 2284203 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2016",
            "endDate": "17-Sep-2024",
            "statusDate": "12-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "29-Jun-2016",
                "endDate": "04-Jan-2018",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "04-Jan-2018",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Mar-2022",
                "endDate": "12-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2023",
                "endDate": "18-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "18-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Mar-2024",
                "predictedDateU50": "17-Sep-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "12-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "By July 2023, submission was under review in China for the treatment of refractory or relapsed follicular lymphoma [ <ulink linkID=\"3008388\" linkType=\"Reference\"> 3008388 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Nov-2017",
            "endDate": "17-Nov-2023",
            "statusDate": "04-May-2023",
            "phaseHighestStatus": "Reg",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Nov-2017",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Mar-2022",
                "endDate": "04-May-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-May-2023",
                "endDate": "17-Nov-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Nov-2023",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": null,
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "sNDA/sBLA Filing",
                "status": "Filed",
                "milestoneDate": "04-May-2023",
                "milestoneExtendedDate": "",
                "notes": "In May 2023, the sNDA file was submitted in European Union for R/R follicular lymphoma and R/R CLL [ <ulink linkID=\"2921924\" linkType=\"Reference\"> 2921924 </ulink>]. </para>",
                "newMilestone": false
              },
              {
                "title": "CHMP Opinion",
                "status": "Positive Opinion",
                "milestoneDate": "12-Oct-2023",
                "milestoneExtendedDate": "",
                "notes": "In October 2023, the CHMP adopted positive opinion for the treatment of refractory or relapsed follicular lymphoma [ <ulink linkID=\"3430894\" linkType=\"Reference\"> 3430894 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "GB"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1745",
              "name": "Follicle center lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US, US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "08-Jul-2024",
            "statusDate": "12-Jul-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Mar-2022",
                "endDate": "12-Jul-2023",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Jul-2023",
                "endDate": "01-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jun-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Feb-2024",
                "predictedDateU50": "08-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US",
              " US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2016",
            "endDate": "25-Dec-2027",
            "statusDate": "19-Feb-2019",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "75%",
            "timeToRegistration": "3.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "29-Jun-2016",
                "endDate": "19-Feb-2019",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "19-Feb-2019",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Dec-2023",
                "endDate": "16-May-2026",
                "successPercentage": "83%",
                "predictedDateL50": "17-Jun-2023",
                "predictedDateU50": "13-Apr-2024",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-May-2026",
                "endDate": "28-Aug-2027",
                "successPercentage": "95%",
                "predictedDateL50": "25-Apr-2025",
                "predictedDateU50": "06-Oct-2026",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "28-Aug-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Mar-2027",
                "predictedDateU50": "25-Dec-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "20-Aug-2020",
                "milestoneExtendedDate": "",
                "notes": "In August 2020, a supplementary IND application was filed in China [ <ulink linkID=\"2305762\" linkType=\"Reference\"> 2305762 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "28-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, an implied clinical trial approval of the drug was obtained for marginal zone B-cell lymphoma in China [ <ulink linkID=\"2312515\" linkType=\"Reference\"> 2312515 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "17-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, primary endpoints (ORR by an independent review committee) of a phase II trial (MAGNOLIA; BGB-3111-214) of zanubrutinib in 68 patients with relapsed/refractory marginal zone lymphoma was met. Overall 68 patients showed ORR of 68.2% as determined by an independent review committee based on the Lugano 2014 classification [ <ulink linkID=\"2472778\" linkType=\"Reference\"> 2472778 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, positive topline results of phase II trial (MAGNOLIA; BGB-3111-214) of zanubrutinib in 68 patients with relapsed/refractory marginal zone lymphoma were presented. Overall 68 patients showed overall response rate (ORR) of 68.2% (primary endpoint) as determined by an independent review committee based on the Lugano 2014 classification [ <ulink linkID=\"2472778\" linkType=\"Reference\"> 2472778 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "",
            "statusDate": "19-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Accelerated Approval",
            "startDate": "04-Sep-2014",
            "endDate": "",
            "statusDate": "19-Feb-2019",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1747",
              "name": "Splenic marginal zone lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Feb-2019",
            "endDate": "09-Nov-2026",
            "statusDate": "19-Feb-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "2.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Feb-2019",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Mar-2022",
                "endDate": "17-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Apr-2025",
                "endDate": "25-Jul-2026",
                "successPercentage": "95%",
                "predictedDateL50": "09-Sep-2024",
                "predictedDateU50": "20-Jul-2025",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jul-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Feb-2026",
                "predictedDateU50": "09-Nov-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, preliminary results from a phase I trial (NCT02343120) for r/r MZL showed that the drug had good safety and efficacy [ <ulink linkID=\"2289128\" linkType=\"Reference\"> 2289128 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, a clinical trial for relapsed and refractory Marginal Zone Lymphoma was expected to complete in August 2021 in China [ <ulink linkID=\"2121055\" linkType=\"Reference\"> 2121055 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1747",
              "name": "Splenic marginal zone lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug",
            "startDate": "19-Feb-2019",
            "endDate": "25-May-2026",
            "statusDate": "19-Feb-2019",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "2.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Feb-2019",
                "endDate": "10-Mar-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-Mar-2022",
                "endDate": "09-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "09-Jun-2025",
                "endDate": "11-Apr-2026",
                "successPercentage": "95%",
                "predictedDateL50": "10-Oct-2024",
                "predictedDateU50": "16-Sep-2025",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Apr-2026",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Jan-2026",
                "predictedDateU50": "25-May-2026",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "01-Aug-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, a clinical trial for relapsed and refractory Marginal Zone Lymphoma was expected to complete in August 2021 in the US [ <ulink linkID=\"2121055\" linkType=\"Reference\"> 2121055 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1747",
              "name": "Splenic marginal zone lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "19-Feb-2019",
            "endDate": "21-May-2024",
            "statusDate": "22-Feb-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Feb-2019",
                "endDate": "22-Feb-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Feb-2022",
                "endDate": "12-Mar-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "12-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "27-Dec-2023",
                "predictedDateU50": "21-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "29-Jun-2016",
            "endDate": "30-Jul-2025",
            "statusDate": "21-Jan-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "89%",
            "timeToRegistration": "1.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "29-Jun-2016",
                "endDate": "30-Jun-2017",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "30-Jun-2017",
                "endDate": "21-Jan-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "27-Mar-2025",
                "successPercentage": "95%",
                "predictedDateL50": "12-Aug-2023",
                "predictedDateU50": "20-Feb-2024",
                "phaseDuration": "1.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Mar-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Oct-2024",
                "predictedDateU50": "30-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, primary endpoint (ORR) of a phase II trial (NCT03145064) in 41 patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma was met. The overall response rate was 29.3%, and the complete response rate was 17.1% with a median follow-up time of 6.8 months. The median duration of response was 4.5 months [ <ulink linkID=\"2284682\" linkType=\"Reference\"> 2284682 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "31-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, topline data of a phase II trial (NCT03145064) in 41 patients with relapsed or refractory non-germinal center diffuse large B-cell lymphoma were presented which showed that the primary endpoint (ORR) was met. The overall response rate was 29.3%, and the complete response rate was 17.1% with a median follow-up time of 6.8 months. The median duration of response was 4.5 months [ <ulink linkID=\"2284682\" linkType=\"Reference\"> 2284682 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "12-Jun-2020",
                "milestoneExtendedDate": "",
                "notes": "In June 2020, preliminary results for r/r non-GCB DLBCL showed that the drug had similar good safety and efficacy [ <ulink linkID=\"2289128\" linkType=\"Reference\"> 2289128 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Dec-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In November 2019, a phase II study (NCT03520920) was expected to complete in December 2020 for non-GCB DLBCL and recurrent or refractory indolent lymphoma [ <ulink linkID=\"2289496\" linkType=\"Reference\"> 2289496 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Filed",
                "milestoneDate": "02-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In December 2020, an IND was filed in China; in January 2021, an implied trial approval was granted for CD79B gene mutant relapsed or refractory diffuse large B-cell lymphoma [ <ulink linkID=\"2386291\" linkType=\"Reference\"> 2386291 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "24-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, an implied trial approval was granted for relapsed or refractory diffuse large B-cell lymphoma [ <ulink linkID=\"2399834\" linkType=\"Reference\"> 2399834 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe (GB, IT)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "24-Sep-2025",
            "statusDate": "21-Jan-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "1.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "21-Jan-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2020",
                "endDate": "05-Jun-2024",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Jun-2024",
                "endDate": "22-Jul-2025",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "16-Sep-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Jul-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Mar-2025",
                "predictedDateU50": "24-Sep-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "GB",
              " IT"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "08-Apr-2025",
            "statusDate": "21-Jan-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "85%",
            "timeToRegistration": "1.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "21-Jan-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2020",
                "endDate": "10-Apr-2024",
                "successPercentage": "89%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Apr-2024",
                "endDate": "26-Feb-2025",
                "successPercentage": "95%",
                "predictedDateL50": "30-Dec-2023",
                "predictedDateU50": "09-Jun-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Feb-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Nov-2024",
                "predictedDateU50": "08-Apr-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "1749",
              "name": "Diffuse large B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Sep-2014",
            "endDate": "03-Jun-2025",
            "statusDate": "21-Jan-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "80%",
            "timeToRegistration": "1.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Sep-2014",
                "endDate": "21-Jan-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jan-2020",
                "endDate": "05-Jun-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "4.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Jun-2024",
                "endDate": "23-Apr-2025",
                "successPercentage": "95%",
                "predictedDateL50": "17-Jan-2024",
                "predictedDateU50": "16-Sep-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "23-Apr-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-Jan-2025",
                "predictedDateU50": "03-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "2404",
              "name": "Lupus nephritis"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "22-Dec-2020",
            "endDate": "11-Mar-2028",
            "statusDate": "25-Feb-2021",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "4.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "22-Dec-2020",
                "endDate": "01-Sep-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "01-Sep-2024",
                "endDate": "12-Oct-2026",
                "successPercentage": "95%",
                "predictedDateL50": "21-May-2024",
                "predictedDateU50": "09-Nov-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "12-Oct-2026",
                "endDate": "20-Dec-2027",
                "successPercentage": "95%",
                "predictedDateL50": "05-Nov-2025",
                "predictedDateU50": "13-Feb-2027",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Dec-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Aug-2027",
                "predictedDateU50": "11-Mar-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2023",
                "milestoneExtendedDate": "31-Aug-2023",
                "notes": "In November 2020, a phase II trial (NCT04643470) for active proliferative lupus nephritis was expected to complete in August 2023 [ <ulink linkID=\"2387723\" linkType=\"Reference\"> 2387723 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "3441",
              "name": "Membranous glomerulonephritis"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Apr-2023",
            "endDate": "11-Jun-2027",
            "statusDate": "17-Apr-2023",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "3.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "17-Apr-2023",
                "endDate": "30-Dec-2025",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Dec-2025",
                "endDate": "20-Mar-2027",
                "successPercentage": "95%",
                "predictedDateL50": "24-Feb-2025",
                "predictedDateU50": "02-May-2026",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "20-Mar-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Oct-2026",
                "predictedDateU50": "11-Jun-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1063251",
              "name": "BeiGene Co Ltd"
            },
            "indication": {
              "id": "10406",
              "name": "Coronavirus disease 19 infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "06-Jul-2020",
            "endDate": "21-Mar-2027",
            "statusDate": "11-May-2020",
            "phaseHighestStatus": "Phase 2",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "3.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "06-Jul-2020",
                "endDate": "13-Mar-2024",
                "successPercentage": "10%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "13-Mar-2024",
                "endDate": "05-Apr-2026",
                "successPercentage": "44%",
                "predictedDateL50": "22-Dec-2023",
                "predictedDateU50": "17-May-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Apr-2026",
                "endDate": "04-Feb-2027",
                "successPercentage": "95%",
                "predictedDateL50": "13-May-2025",
                "predictedDateU50": "08-Aug-2026",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "04-Feb-2027",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-Oct-2026",
                "predictedDateU50": "21-Mar-2027",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Endpoints Met",
                "status": "Negative Outcome",
                "milestoneDate": "08-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, negative top-line data were reported from phase II study (NCT04382586). The study did not meet the co-primary efficacy endpoints [ <ulink linkID=\"2432897\" linkType=\"Reference\"> 2432897 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Negative Outcome",
                "milestoneDate": "08-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, negative top-line data were reported from phase II study (NCT04382586). The study did not meet the co-primary efficacy endpoints [ <ulink linkID=\"2432897\" linkType=\"Reference\"> 2432897 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "80976",
        "displayName": "trastuzumab biosimilar, Shanghai Henlius/Jacobson Pharma",
        "drugPrograms": [
          {
            "company": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2023",
            "endDate": "11-Mar-2024",
            "statusDate": "14-Feb-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2023",
                "endDate": "10-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "11-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "indication": {
              "id": "1011",
              "name": "Esophagus tumor"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2023",
            "endDate": "04-Mar-2024",
            "statusDate": "14-Feb-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2023",
                "endDate": "03-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "14-Dec-2023",
                "predictedDateU50": "04-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2023",
            "endDate": "11-Mar-2024",
            "statusDate": "14-Feb-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2023",
                "endDate": "10-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "10-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "11-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Feb-2023",
            "endDate": "09-Mar-2024",
            "statusDate": "14-Feb-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "14-Feb-2023",
                "endDate": "08-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "15-Dec-2023",
                "predictedDateU50": "09-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1073079",
              "name": "Shanghai Henlius Biotech Inc"
            },
            "indication": {
              "id": "49",
              "name": "Breast tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (PL)"
            },
            "principalCompany": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "21-Jun-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "PL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1073079",
              "name": "Shanghai Henlius Biotech Inc"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (PL)"
            },
            "principalCompany": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "21-Jun-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "PL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1073079",
              "name": "Shanghai Henlius Biotech Inc"
            },
            "indication": {
              "id": "3666",
              "name": "Metastatic stomach cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU (PL)"
            },
            "principalCompany": {
              "id": "1052220",
              "name": "Accord Healthcare Inc"
            },
            "designation": null,
            "startDate": "",
            "endDate": "",
            "statusDate": "21-Jun-2019",
            "phaseHighestStatus": "partner",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [],
            "catalysts": [],
            "sourceCountryIds": [
              "PL"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "81474",
        "displayName": "axicabtagene ciloleucel",
        "drugPrograms": [
          {
            "company": {
              "id": "1056870",
              "name": "Kite Pharma Inc"
            },
            "indication": {
              "id": "1746",
              "name": "Marginal zone B-cell lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Orphan Drug, Priority Review",
            "startDate": "08-May-2017",
            "endDate": "",
            "statusDate": "04-Sep-2020",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "08-May-2017",
                "endDate": "04-Sep-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.3",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "04-Sep-2020",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1181265",
              "name": "Fosun Kite Biotechnology Co Ltd"
            },
            "indication": {
              "id": "316",
              "name": "B-cell lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Priority Review",
            "startDate": "26-Mar-2023",
            "endDate": "27-Aug-2024",
            "statusDate": "26-Mar-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "26-Mar-2023",
                "endDate": "17-Jun-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "17-Jun-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Feb-2024",
                "predictedDateU50": "27-Aug-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "18-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the drug was conditionally approved for the treatment of adult large B-cell lymphoma who failed first-line immunochemotherapy or relapsed within 12 months [ <ulink linkID=\"3016319\" linkType=\"Reference\"> 3016319 </ulink> ].  </para>",
                "newMilestone": false
              },
              {
                "title": "Conditional approval",
                "status": "Granted",
                "milestoneDate": "18-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, the drug was conditionally approved for the treatment of adult large B-cell lymphoma who failed first-line immunochemotherapy or relapsed within 12 months [ <ulink linkID=\"3016319\" linkType=\"Reference\"> 3016319 </ulink> ].  </para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1181265",
              "name": "Fosun Kite Biotechnology Co Ltd"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Breakthrough Therapy",
            "startDate": "23-Oct-2018",
            "endDate": "",
            "statusDate": "23-Oct-2018",
            "phaseHighestStatus": "Repositioned",
            "probabilityOfSuccess": "100%",
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "23-Oct-2018",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "95620",
        "displayName": "cosibelimab",
        "drugPrograms": [
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "03-Dec-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "15-Aug-2025",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "15-Aug-2025",
                "endDate": "25-Dec-2027",
                "successPercentage": "11%",
                "predictedDateL50": "06-Apr-2024",
                "predictedDateU50": "27-Sep-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "25-Dec-2027",
                "endDate": "25-Aug-2030",
                "successPercentage": "18%",
                "predictedDateL50": "02-Nov-2026",
                "predictedDateU50": "03-Jun-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Aug-2030",
                "endDate": "03-Oct-2031",
                "successPercentage": "87%",
                "predictedDateL50": "07-Jul-2029",
                "predictedDateU50": "26-Jan-2031",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Oct-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-May-2031",
                "predictedDateU50": "03-Dec-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "205",
              "name": "Melanoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "21-Sep-2030",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "13-Nov-2024",
                "successPercentage": "68%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Nov-2024",
                "endDate": "08-Dec-2026",
                "successPercentage": "9%",
                "predictedDateL50": "13-Feb-2024",
                "predictedDateU50": "03-Jun-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Dec-2026",
                "endDate": "06-Jul-2029",
                "successPercentage": "15%",
                "predictedDateL50": "17-Nov-2025",
                "predictedDateU50": "14-May-2027",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "06-Jul-2029",
                "endDate": "30-Jul-2030",
                "successPercentage": "65%",
                "predictedDateL50": "25-May-2028",
                "predictedDateU50": "17-Nov-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Jul-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Mar-2030",
                "predictedDateU50": "21-Sep-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2023",
            "endDate": "02-May-2024",
            "statusDate": "04-Jan-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "81%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "04-Jan-2023",
                "endDate": "02-Apr-2024",
                "successPercentage": "81%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Feb-2024",
                "predictedDateU50": "02-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In August 2023, drug launch for the treatment of locally advanced and metastatic cSCC was expected in 2024 [ <ulink linkID=\"3040949\" linkType=\"Reference\"> 3040949 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "03-Jan-2024",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, the US FDA accepted the BLA filling and assigned a Prescription Drug User Fee Act (PDUFA) goal date of January 3, 2024 [ <ulink linkID=\"2879224\" linkType=\"Reference\">  2879224 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "307",
              "name": "Squamous cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Paediatric Investigation Plan",
            "startDate": "20-Sep-2017",
            "endDate": "23-Jun-2029",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "35%",
            "timeToRegistration": "5.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Dec-2023",
                "endDate": "03-Jan-2026",
                "successPercentage": "60%",
                "predictedDateL50": "12-Dec-2022",
                "predictedDateU50": "04-Sep-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Jan-2026",
                "endDate": "25-May-2028",
                "successPercentage": "72%",
                "predictedDateL50": "13-Dec-2024",
                "predictedDateU50": "09-Jun-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-May-2028",
                "endDate": "14-May-2029",
                "successPercentage": "85%",
                "predictedDateL50": "14-May-2027",
                "predictedDateU50": "10-Oct-2028",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-May-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Jan-2029",
                "predictedDateU50": "23-Jun-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "01-May-2019",
                "milestoneExtendedDate": "",
                "notes": "In May 2019, positive interim results from the phase I trial (NCT03212404) in patients with advanced cancers were reported. Objective response rates were greater than 40% in first-line non-small cell lung cancer and cutaneous squamous cell carcinoma and drug was found to be safe and well-tolerated [<ulink linkType=\"Reference\" linkID=\"2147433\">2147433</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, updated positive interim results from the phase I trial (NCT03212404) in patients with cutaneous squamous cell carcinoma were reported [<ulink linkType=\"Reference\" linkID=\"2323115\">2323115</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Positive Outcome",
                "milestoneDate": "31-Jul-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, top-line data from the phase I trial (NCT03212404) in patients with cutaneous squamous cell carcinoma were expected in mid-2021 [<ulink linkType=\"Reference\" linkID=\"2323115\">2323115</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, positive topline data were reported for registration-enabling cohort of a fixed dose of 800 mg cosibelimab q2w in the phase I trial (NCT03212404) in patients with metastatic cSCC [ <ulink linkID=\"2603507\" linkType=\"Reference\">  2603507 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "25-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, positive topline data were reported for registration-enabling cohort of a fixed dose of 800 mg cosibelimab q2w in the phase I trial (NCT03212404) in patients with metastatic cSCC [ <ulink linkID=\"2603507\" linkType=\"Reference\">  2603507 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Paediatric Investigation Plan",
                "status": "Granted",
                "milestoneDate": "13-May-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, the EMA and MHRA approved PIP that month  for  cutaneous squamous cell carcinoma (cSCC) [ <ulink linkID=\"2669475\" linkType=\"Reference\">  2669475 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive data from phase I trial (NCT03212404; CK-301-101) demonstrating good efficacy were reported [  <ulink linkID=\"2688333\" linkType=\"Reference\">  2688333 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive long term data were reported for registration-enabling cohort of a fixed dose of 800 mg cosibelimab q2w in the phase I trial (NCT03212404) in patients with metastatic and locally advanced cSCC [ <ulink linkID=\"3027109\" linkType=\"Reference\"> 3027109 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "725",
              "name": "Solid tumor"
            },
            "country": {
              "id": "EU",
              "name": "EU (PL)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "11-Nov-2029",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "5.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "10-Dec-2023",
                "successPercentage": "85%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "10-Dec-2023",
                "endDate": "03-Jan-2026",
                "successPercentage": "9%",
                "predictedDateL50": "17-Dec-2022",
                "predictedDateU50": "18-Aug-2024",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "03-Jan-2026",
                "endDate": "03-Sep-2028",
                "successPercentage": "18%",
                "predictedDateL50": "13-Dec-2024",
                "predictedDateU50": "09-Jun-2026",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Sep-2028",
                "endDate": "22-Sep-2029",
                "successPercentage": "77%",
                "predictedDateL50": "17-Jul-2027",
                "predictedDateU50": "04-Feb-2029",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "22-Sep-2029",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-May-2029",
                "predictedDateU50": "11-Nov-2029",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "21-Mar-2018",
                "milestoneExtendedDate": "",
                "notes": "In March 2018, the dose escalation portion of the phase I trial (NCT03212404) in patients with advanced cancers was completed. Preliminary data were reported. Data demonstrated that CK-301 was safe and well tolerated across three fixed dose levels [<ulink linkType=\"Reference\" linkID=\"2016184\">2016184</ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2018",
                "milestoneExtendedDate": "31-Dec-2018",
                "notes": "In March 2018, initial data from the dose expansion cohort in the phase I trial (NCT03212404) in patients with advanced cancers were expected in the second half of 2018 [<ulink linkType=\"Reference\" linkID=\"2016184\">2016184</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "PL"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "989",
              "name": "Colorectal tumor"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "09-May-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "28-Mar-2025",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "28-Mar-2025",
                "endDate": "02-Jul-2027",
                "successPercentage": "8%",
                "predictedDateL50": "09-Mar-2024",
                "predictedDateU50": "05-Jan-2026",
                "phaseDuration": "2.3",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Jul-2027",
                "endDate": "28-Jan-2030",
                "successPercentage": "11%",
                "predictedDateL50": "15-May-2026",
                "predictedDateU50": "03-Dec-2027",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "28-Jan-2030",
                "endDate": "09-Mar-2031",
                "successPercentage": "75%",
                "predictedDateL50": "17-Dec-2028",
                "predictedDateU50": "11-Jun-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "09-Mar-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "28-Oct-2030",
                "predictedDateU50": "09-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1240",
              "name": "Mesothelioma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "16-Jan-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "17-Mar-2025",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "17-Mar-2025",
                "endDate": "02-May-2027",
                "successPercentage": "11%",
                "predictedDateL50": "05-Mar-2024",
                "predictedDateU50": "22-Dec-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2027",
                "endDate": "03-Nov-2029",
                "successPercentage": "13%",
                "predictedDateL50": "06-Apr-2026",
                "predictedDateU50": "06-Oct-2027",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "03-Nov-2029",
                "endDate": "25-Nov-2030",
                "successPercentage": "87%",
                "predictedDateL50": "30-Sep-2028",
                "predictedDateU50": "21-Mar-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Nov-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Jul-2030",
                "predictedDateU50": "16-Jan-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "06-Jan-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "17-Mar-2025",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "17-Mar-2025",
                "endDate": "02-May-2027",
                "successPercentage": "11%",
                "predictedDateL50": "05-Mar-2024",
                "predictedDateU50": "22-Dec-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-May-2027",
                "endDate": "21-Oct-2029",
                "successPercentage": "12%",
                "predictedDateL50": "06-Apr-2026",
                "predictedDateU50": "06-Oct-2027",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "21-Oct-2029",
                "endDate": "14-Nov-2030",
                "successPercentage": "83%",
                "predictedDateL50": "26-Sep-2028",
                "predictedDateU50": "10-Mar-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Nov-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "08-Jul-2030",
                "predictedDateU50": "06-Jan-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1705",
              "name": "Endometrioid carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "04-Aug-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "01-Jul-2025",
                "successPercentage": "92%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-Jul-2025",
                "endDate": "16-Aug-2027",
                "successPercentage": "12%",
                "predictedDateL50": "08-Apr-2024",
                "predictedDateU50": "01-Jun-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "16-Aug-2027",
                "endDate": "16-Apr-2030",
                "successPercentage": "20%",
                "predictedDateL50": "21-Jul-2026",
                "predictedDateU50": "20-Jan-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "16-Apr-2030",
                "endDate": "01-Jun-2031",
                "successPercentage": "87%",
                "predictedDateL50": "26-Feb-2029",
                "predictedDateU50": "17-Sep-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jun-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "17-Jan-2031",
                "predictedDateU50": "04-Aug-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1766",
              "name": "Renal cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "02-Feb-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "07-Feb-2025",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "07-Feb-2025",
                "endDate": "18-Mar-2027",
                "successPercentage": "12%",
                "predictedDateL50": "19-Feb-2024",
                "predictedDateU50": "12-Oct-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "18-Mar-2027",
                "endDate": "25-Oct-2029",
                "successPercentage": "16%",
                "predictedDateL50": "24-Feb-2026",
                "predictedDateU50": "27-Aug-2027",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "25-Oct-2029",
                "endDate": "02-Dec-2030",
                "successPercentage": "79%",
                "predictedDateL50": "12-Sep-2028",
                "predictedDateU50": "18-Mar-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Dec-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jul-2030",
                "predictedDateU50": "02-Feb-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "03-Oct-2030",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.7",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "01-Dec-2024",
                "successPercentage": "75%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-Dec-2024",
                "endDate": "09-Jan-2027",
                "successPercentage": "11%",
                "predictedDateL50": "15-Feb-2024",
                "predictedDateU50": "17-Jun-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "09-Jan-2027",
                "endDate": "23-Sep-2029",
                "successPercentage": "19%",
                "predictedDateL50": "18-Dec-2025",
                "predictedDateU50": "20-Jun-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "23-Sep-2029",
                "endDate": "26-Aug-2030",
                "successPercentage": "89%",
                "predictedDateL50": "05-Aug-2028",
                "predictedDateU50": "03-Mar-2030",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Aug-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "12-May-2030",
                "predictedDateU50": "03-Oct-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "1771",
              "name": "Transitional cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "04-Jun-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "13-May-2025",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-May-2025",
                "endDate": "21-Jun-2027",
                "successPercentage": "12%",
                "predictedDateL50": "25-Mar-2024",
                "predictedDateU50": "23-Feb-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jun-2027",
                "endDate": "05-Mar-2030",
                "successPercentage": "20%",
                "predictedDateL50": "30-May-2026",
                "predictedDateU50": "30-Nov-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "05-Mar-2030",
                "endDate": "06-Apr-2031",
                "successPercentage": "88%",
                "predictedDateL50": "15-Jan-2029",
                "predictedDateU50": "13-Aug-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Apr-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "29-Nov-2030",
                "predictedDateU50": "04-Jun-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "2170",
              "name": "Skin cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Jan-2023",
            "endDate": "02-May-2024",
            "statusDate": "04-Jan-2023",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "84%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "04-Jan-2023",
                "endDate": "02-Apr-2024",
                "successPercentage": "84%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Apr-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Feb-2024",
                "predictedDateU50": "02-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Predicted Launch Date",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In August 2023, drug launch for the treatment of locally advanced and metastatic cSCC was expected in 2024 [ <ulink linkID=\"3040949\" linkType=\"Reference\"> 3040949 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "2170",
              "name": "Skin cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "16-Jul-2030",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "6.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "26-Jul-2024",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-Jul-2024",
                "endDate": "20-Aug-2026",
                "successPercentage": "9%",
                "predictedDateL50": "29-Jul-2023",
                "predictedDateU50": "21-Apr-2025",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Aug-2026",
                "endDate": "10-May-2029",
                "successPercentage": "21%",
                "predictedDateL50": "30-Jul-2025",
                "predictedDateU50": "24-Jan-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-May-2029",
                "endDate": "27-May-2030",
                "successPercentage": "83%",
                "predictedDateL50": "19-Mar-2028",
                "predictedDateU50": "18-Oct-2029",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-May-2030",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Jan-2030",
                "predictedDateU50": "16-Jul-2030",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "16-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, positive data from phase I trial (NCT03212404; CK-301-101) demonstrating good efficacy were reported [  <ulink linkID=\"2688333\" linkType=\"Reference\">  2688333 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "27-Jul-2023",
                "milestoneExtendedDate": "",
                "notes": "In July 2023, positive long term data were reported for registration-enabling cohort of a fixed dose of 800 mg cosibelimab q2w in the phase I trial (NCT03212404) in patients with metastatic and locally advanced cSCC [ <ulink linkID=\"3027109\" linkType=\"Reference\"> 3027109 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "26-May-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "13-May-2025",
                "successPercentage": "91%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-May-2025",
                "endDate": "21-Jun-2027",
                "successPercentage": "12%",
                "predictedDateL50": "25-Mar-2024",
                "predictedDateU50": "23-Feb-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Jun-2027",
                "endDate": "19-Feb-2030",
                "successPercentage": "18%",
                "predictedDateL50": "30-May-2026",
                "predictedDateU50": "30-Nov-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Feb-2030",
                "endDate": "26-Mar-2031",
                "successPercentage": "85%",
                "predictedDateL50": "01-Jan-2029",
                "predictedDateU50": "23-Jul-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "26-Mar-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "16-Nov-2030",
                "predictedDateU50": "26-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "3235",
              "name": "Merkel cell carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "16-May-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "26-May-2025",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-May-2025",
                "endDate": "20-Jun-2027",
                "successPercentage": "9%",
                "predictedDateL50": "23-Mar-2024",
                "predictedDateU50": "07-Mar-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2027",
                "endDate": "10-Mar-2030",
                "successPercentage": "21%",
                "predictedDateL50": "30-May-2026",
                "predictedDateU50": "24-Nov-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Mar-2030",
                "endDate": "27-Mar-2031",
                "successPercentage": "83%",
                "predictedDateL50": "17-Jan-2029",
                "predictedDateU50": "18-Aug-2030",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Mar-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "18-Nov-2030",
                "predictedDateU50": "16-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1106471",
              "name": "Checkpoint Therapeutics Inc"
            },
            "indication": {
              "id": "3673",
              "name": "Metastatic head and neck cancer"
            },
            "country": {
              "id": "EU",
              "name": "Europe"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "20-Sep-2017",
            "endDate": "04-May-2031",
            "statusDate": "20-Sep-2017",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "20-Sep-2017",
                "endDate": "26-May-2025",
                "successPercentage": "86%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "7.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "26-May-2025",
                "endDate": "20-Jun-2027",
                "successPercentage": "9%",
                "predictedDateL50": "23-Mar-2024",
                "predictedDateU50": "07-Mar-2026",
                "phaseDuration": "2.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "20-Jun-2027",
                "endDate": "24-Feb-2030",
                "successPercentage": "19%",
                "predictedDateL50": "30-May-2026",
                "predictedDateU50": "24-Nov-2027",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Feb-2030",
                "endDate": "15-Mar-2031",
                "successPercentage": "79%",
                "predictedDateL50": "04-Jan-2029",
                "predictedDateU50": "28-Jul-2030",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Mar-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "05-Nov-2030",
                "predictedDateU50": "04-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jul-2021",
                "milestoneExtendedDate": "31-Dec-2021",
                "notes": "In November 2020, top-line data from the phase I trial (NCT03212404) were expected in the second half of 2021 in patients with advanced cancers [2357210].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "X5"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "31093",
              "name": "TG Therapeutics Inc"
            },
            "indication": {
              "id": "161",
              "name": "Hodgkins disease"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Apr-2019",
            "endDate": "05-Jul-2031",
            "statusDate": "17-Apr-2019",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Apr-2019",
                "endDate": "01-May-2025",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-May-2025",
                "endDate": "21-Nov-2027",
                "successPercentage": "16%",
                "predictedDateL50": "20-Mar-2024",
                "predictedDateU50": "05-Jan-2026",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "21-Nov-2027",
                "endDate": "17-Jul-2030",
                "successPercentage": "25%",
                "predictedDateL50": "27-Aug-2026",
                "predictedDateU50": "02-Jun-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "17-Jul-2030",
                "endDate": "21-May-2031",
                "successPercentage": "89%",
                "predictedDateL50": "28-May-2029",
                "predictedDateU50": "12-Dec-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "21-May-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "11-Feb-2031",
                "predictedDateU50": "05-Jul-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In December 2018, a phase I trial was expected to complete in August 2022 [<ulink linkType=\"Reference\" linkID=\"2106570\">2106570</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "31093",
              "name": "TG Therapeutics Inc"
            },
            "indication": {
              "id": "319",
              "name": "Non-Hodgkin lymphoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "17-Apr-2019",
            "endDate": "13-Apr-2031",
            "statusDate": "17-Apr-2019",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "17-Apr-2019",
                "endDate": "01-May-2025",
                "successPercentage": "80%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "01-May-2025",
                "endDate": "02-Oct-2027",
                "successPercentage": "16%",
                "predictedDateL50": "20-Mar-2024",
                "predictedDateU50": "05-Jan-2026",
                "phaseDuration": "2.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "02-Oct-2027",
                "endDate": "24-Apr-2030",
                "successPercentage": "20%",
                "predictedDateL50": "25-Jul-2026",
                "predictedDateU50": "09-Mar-2028",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "24-Apr-2030",
                "endDate": "27-Feb-2031",
                "successPercentage": "81%",
                "predictedDateL50": "15-Mar-2029",
                "predictedDateU50": "07-Sep-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Feb-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Nov-2030",
                "predictedDateU50": "13-Apr-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Aug-2022",
                "milestoneExtendedDate": "31-Aug-2022",
                "notes": "In December 2018, a phase I trial was expected to complete in August 2022 [<ulink linkType=\"Reference\" linkID=\"2106570\">2106570</ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "31093",
              "name": "TG Therapeutics Inc"
            },
            "indication": {
              "id": "2054",
              "name": "Hematological neoplasm"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2018",
            "endDate": "30-May-2031",
            "statusDate": "30-Nov-2018",
            "phaseHighestStatus": "Phase 1",
            "probabilityOfSuccess": "5%",
            "timeToRegistration": "7.4",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "30-Nov-2018",
                "endDate": "13-Apr-2025",
                "successPercentage": "76%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.4",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 2",
                "startDate": "13-Apr-2025",
                "endDate": "08-Oct-2027",
                "successPercentage": "15%",
                "predictedDateL50": "24-Mar-2024",
                "predictedDateU50": "16-Nov-2025",
                "phaseDuration": "2.5",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "08-Oct-2027",
                "endDate": "14-Jun-2030",
                "successPercentage": "40%",
                "predictedDateL50": "17-Jul-2026",
                "predictedDateU50": "12-Mar-2028",
                "phaseDuration": "2.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "14-Jun-2030",
                "endDate": "15-Apr-2031",
                "successPercentage": "89%",
                "predictedDateL50": "24-Apr-2029",
                "predictedDateU50": "15-Nov-2030",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "15-Apr-2031",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "09-Jan-2031",
                "predictedDateU50": "30-May-2031",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "99330",
        "displayName": "sabizabulin",
        "drugPrograms": [
          {
            "company": {
              "id": "1114402",
              "name": "Veru Inc"
            },
            "indication": {
              "id": "3246",
              "name": "Hormone refractory prostate cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "18-Jan-2019",
            "endDate": "28-Jun-2025",
            "statusDate": "07-Jun-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "48%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Jan-2019",
                "endDate": "24-Jun-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.4",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "24-Jun-2021",
                "endDate": "19-Aug-2024",
                "successPercentage": "53%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "3.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "19-Aug-2024",
                "endDate": "29-May-2025",
                "successPercentage": "90%",
                "predictedDateL50": "28-Mar-2024",
                "predictedDateU50": "10-Dec-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "29-May-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "20-Feb-2025",
                "predictedDateU50": "28-Jun-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Aug-2019",
                "milestoneExtendedDate": "",
                "notes": "In August 2019, interim data from phase Ib/II trial (NCT03752099) were reported [ <ulink linkID=\"2201213\" linkType=\"Reference\"> 2201213 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "Source Date: 2/02/2020; Phase: C2;  In February 2020, phase II portion results from phase Ib/II trial (NCT03752099) were expected by the end of the year 2020 for advanced metastatic castration resistant prostate cancer [ <ulink linkID=\"2249724\" linkType=\"Reference\"> 2249724 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "05-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, phase Ib primary endpoint (MTD) of a phase Ib/II trial (NCT03752099) for advanced metastatic castration resistant prostate cancer was met. The MTD of VERU-111 was determined to be 72 mg [ <ulink linkID=\"2274341\" linkType=\"Reference\"> 2274341 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "05-May-2020",
                "milestoneExtendedDate": "",
                "notes": "In May 2020, interim data from phase Ib/II trial (NCT03752099) for advanced metastatic castration resistant prostate cancer were reported [ <ulink linkID=\"2274341\" linkType=\"Reference\"> 2274341 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected IND Filing",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Oct-2020",
                "milestoneExtendedDate": "31-Dec-2020",
                "notes": "In July 2020, the company planned to submit a protocol to FDA for a phase III study for metastatic castration-resistant prostate cancer, in the fourth quarter of 2020 [ <ulink linkID=\"2303619\" linkType=\"Reference\"> 2303619 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Dec-2020",
                "milestoneExtendedDate": "",
                "notes": "In November 2018, the trial was expected to complete in December 22, 2020 [ <ulink linkID=\"2100366\" linkType=\"Reference\"> 2100366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "31-Mar-2021",
                "notes": "In July 2020, a phase III study for metastatic castration-resistant prostate cancer was expected to begin in the first quarter of 2021 [ <ulink linkID=\"2303619\" linkType=\"Reference\"> 2303619 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2021",
                "milestoneExtendedDate": "30-Jun-2021",
                "notes": "In December 2020, data from the phase I/II trial treatment of advanced metastatic castration resistant prostate cancer were expected in the first half of 2021 [2376232].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned (Month)",
                "milestoneDate": "01-Apr-2021",
                "milestoneExtendedDate": "30-Apr-2021",
                "notes": "In April 2021, a phase III trial (NCT04844749; VERACITY) in patients with metastatic castration-resistant prostate cancer was planned to initiate later that month [ <ulink linkID=\"2437692\" linkType=\"Reference\"> 2437692 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned",
                "milestoneDate": "21-Sep-2021",
                "milestoneExtendedDate": "",
                "notes": "In September 2021, further data from phase Ib/II trial ( NCT03752099 ; V1011101) to evaluate the safety and tolerability of drug in subjects with advanced metastatic castration resistant prostate cancer were expected later that month [ <ulink linkID=\"2525488\" linkType=\"Reference\">  2525488 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-Aug-2024",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, a phase III trial (NCT04844749; VERACITY) in patients with metastatic castration-resistant prostate cancer was expected to complete in August 2024 [ <ulink linkID=\"2437692\" linkType=\"Reference\"> 2437692 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1114402",
              "name": "Veru Inc"
            },
            "indication": {
              "id": "10406",
              "name": "Coronavirus disease 19 infection"
            },
            "country": {
              "id": "EU",
              "name": "EU (BG)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Dec-2021",
            "endDate": "09-Jan-2025",
            "statusDate": "02-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "86%",
            "timeToRegistration": "1.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Dec-2021",
                "endDate": "10-Dec-2023",
                "successPercentage": "94%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "01-Dec-2024",
                "successPercentage": "92%",
                "predictedDateL50": "27-Jun-2023",
                "predictedDateU50": "25-Feb-2024",
                "phaseDuration": "1.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Dec-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "04-Aug-2024",
                "predictedDateU50": "09-Jan-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In December 2021, results from phase III study (  <ulink linkID=\"484883\" linkType=\"Protocol\">   NCT04842747  </ulink>; V3011902) evaluating efficacy of VERU-111 in the treatment of SARS-CoV-2 Infection were expected in first half of 2022 [ <ulink linkID=\"2576337\" linkType=\"Reference\">  2576337 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive interim data for phase III trial ( NCT04842747) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2648664\" linkType=\"Reference\">  2648664 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, trial endpoint from phase III trial ( NCT04842747) were met [  <ulink linkID=\"2648664\" linkType=\"Reference\">  2648664 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "06-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the phase III trial (NCT04842747) in SARS-CoV-2 was completed [ <ulink linkID=\"2437542\" linkType=\"Reference\">  2437542 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "BG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1114402",
              "name": "Veru Inc"
            },
            "indication": {
              "id": "10406",
              "name": "Coronavirus disease 19 infection"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Fast Track, Emergency Use Authorization",
            "startDate": "18-Jun-2020",
            "endDate": "07-May-2024",
            "statusDate": "07-Jun-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "93%",
            "timeToRegistration": "0.3",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "18-Jun-2020",
                "endDate": "10-May-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2021",
                "endDate": "07-Jun-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Jun-2022",
                "endDate": "05-Mar-2024",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.7",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "05-Mar-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "21-Dec-2023",
                "predictedDateU50": "07-May-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Trial Top line Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "08-Feb-2021",
                "milestoneExtendedDate": "",
                "notes": "In February 2021, positive efficacy and safety from phase II trial (NCT04388826) for COVID-19 were reported [ <ulink linkID=\"2403520\" linkType=\"Reference\"> 2403520 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Start Date",
                "status": "Planned",
                "milestoneDate": "30-Apr-2021",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, a phase III study (NCT04842747) was to begin later that month in patients with SARS-CoV-2 infection [ <ulink linkID=\"2437542\" linkType=\"Reference\"> 2437542 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In December 2021, results from phase III study (  <ulink linkID=\"484883\" linkType=\"Protocol\">   NCT04842747  </ulink>; V3011902) evaluating efficacy of VERU-111 in the treatment of SARS-CoV-2 Infection were expected in first half of 2022 [ <ulink linkID=\"2576337\" linkType=\"Reference\">  2576337 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Fast Track",
                "status": "Granted",
                "milestoneDate": "31-Jan-2022",
                "milestoneExtendedDate": "",
                "notes": "In January 2022, Fast Track Designation was granted by the FDA for the phase III COVID-19 program [ <ulink linkID=\"2616716\" linkType=\"Reference\">  2616716 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "19-Mar-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2021, a phase III study (NCT04842747) was expected to complete in March 2022 in patients with SARS-CoV-2 infection [ <ulink linkID=\"2437542\" linkType=\"Reference\"> 2437542 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Emergency Use Authorization",
                "status": "Planned (Quarter)",
                "milestoneDate": "01-Apr-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In May 2022, the company planned to submit an EUA application in the second quarter of 2022 [  <ulink linkID=\"2667445\" linkType=\"Reference\">  2667445 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "11-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, positive interim data for phase III trial ( NCT04842747) demonstrating good safety and efficacy were reported [  <ulink linkID=\"2648664\" linkType=\"Reference\">  2648664 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "11-Apr-2022",
                "milestoneExtendedDate": "",
                "notes": "In April 2022, trial endpoint from phase III trial ( NCT04842747) were met [  <ulink linkID=\"2648664\" linkType=\"Reference\">  2648664 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Emergency Use Authorization",
                "status": "Filed",
                "milestoneDate": "07-Jun-2022",
                "milestoneExtendedDate": "",
                "notes": "In June 2022, company submitted emergency use authorization (EUA) application to the US FDA for the treatment of moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS) [  <ulink linkID=\"2682949\" linkType=\"Reference\">  2682949 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "06-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the phase III trial (NCT04842747) in SARS-CoV-2 was completed [ <ulink linkID=\"2437542\" linkType=\"Reference\">  2437542 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Emergency Use Authorization",
                "status": "Rejected",
                "milestoneDate": "02-Mar-2023",
                "milestoneExtendedDate": "",
                "notes": "In March 2023, the US FDA had declined to grant emergency use authorization (EUA) application for the treatment of moderate to severe hospitalized COVID-19 patients at high risk for developing Acute Respiratory Distress Syndrome (ARDS) [  <ulink linkID=\"2843534\" linkType=\"Reference\">  2843534  </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1114402",
              "name": "Veru Inc"
            },
            "indication": {
              "id": "13048",
              "name": "Acute respiratory distress syndrome"
            },
            "country": {
              "id": "EU",
              "name": "EU (BG)"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "02-Dec-2021",
            "endDate": "19-Jul-2025",
            "statusDate": "02-Dec-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "64%",
            "timeToRegistration": "1.5",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "02-Dec-2021",
                "endDate": "10-Jul-2024",
                "successPercentage": "67%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Jul-2024",
                "endDate": "11-Jun-2025",
                "successPercentage": "95%",
                "predictedDateL50": "04-Feb-2024",
                "predictedDateU50": "26-Sep-2024",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "11-Jun-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Feb-2025",
                "predictedDateU50": "19-Jul-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial Outcome Announcements",
                "status": "Planned (Half)",
                "milestoneDate": "01-Jan-2022",
                "milestoneExtendedDate": "30-Jun-2022",
                "notes": "In December 2021, results from phase III study ( <ulink linkID=\"484883\" linkType=\"Protocol\"> NCT04842747 </ulink>; V3011902) evaluating efficacy of VERU-111 in the treatment of SARS-CoV-2 Infection were expected in first half of 2022 [ <ulink linkID=\"2576337\" linkType=\"Reference\"> 2576337 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Completion/Final Data Reported",
                "status": "Other Outcome",
                "milestoneDate": "06-Jul-2022",
                "milestoneExtendedDate": "",
                "notes": "In July 2022, the phase III trial (NCT04842747) in SARS-CoV-2 was completed [ <ulink linkID=\"2437542\" linkType=\"Reference\"> 2437542 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "BG"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "1114402",
              "name": "Veru Inc"
            },
            "indication": {
              "id": "13048",
              "name": "Acute respiratory distress syndrome"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": "Emergency Use Authorization",
            "startDate": "19-Jun-2020",
            "endDate": "",
            "statusDate": "07-Jun-2022",
            "phaseHighestStatus": "Inactive",
            "probabilityOfSuccess": null,
            "timeToRegistration": "0.0",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "19-Jun-2020",
                "endDate": "10-May-2021",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "10-May-2021",
                "endDate": "07-Jun-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.1",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "07-Jun-2022",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      },
      {
        "drugId": "115033",
        "displayName": "atezolizumab (sc Enhanze), Roche",
        "drugPrograms": [
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "24-Feb-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "25-Jan-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "25-Jan-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "19-Dec-2023",
                "predictedDateU50": "24-Feb-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the MAA was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain [ <ulink linkID=\"3054005\" linkType=\"Reference\"> 3054005 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1261",
              "name": "Small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jun-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Sep-2022",
            "endDate": "04-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Sep-2022",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "03-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "03-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Dec-2023",
                "predictedDateU50": "04-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, MAA was filed in EU [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In October 2021, filing for non-small cell lung cancer was expected in 2023 [ <ulink linkID=\"2551964\" linkType=\"Reference\">  2551964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the MAA was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain [ <ulink linkID=\"3054005\" linkType=\"Reference\"> 3054005 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05171777)  for non-small cell lung cancer in the US, Italy, Republic of Korea, Poland and Russian Federation was expected to complete in December 2023 [  <ulink linkID=\"2591344\" linkType=\"Reference\">  2591344 </ulink> ].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1262",
              "name": "Non-small-cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "10-Sep-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "10-Sep-2022",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.2",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jun-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, BLA was filed in the US [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected NDA/BLA Filing",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2023",
                "milestoneExtendedDate": "31-Dec-2023",
                "notes": "In October 2021, filing for non-small cell lung cancer was expected in 2023 [ <ulink linkID=\"2551964\" linkType=\"Reference\">  2551964 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "29-Dec-2023",
                "milestoneExtendedDate": "",
                "notes": "In December 2021, a phase II trial (NCT05171777)  for non-small cell lung cancer in the US, Italy, Republic of Korea, Poland and Russian Federation was expected to complete in December 2023 [  <ulink linkID=\"2591344\" linkType=\"Reference\">  2591344 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "03-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "02-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Dec-2023",
                "predictedDateU50": "03-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the MAA was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain [ <ulink linkID=\"3054005\" linkType=\"Reference\"> 3054005 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "1767",
              "name": "Hepatocellular carcinoma"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-May-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2021",
            "endDate": "09-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-May-2021",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "07-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Dec-2023",
                "predictedDateU50": "09-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, MAA was filed in EU [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the MAA was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain [ <ulink linkID=\"3054005\" linkType=\"Reference\"> 3054005 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "Japan",
              "name": "Japan"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2021",
            "endDate": "13-Nov-2028",
            "statusDate": "03-May-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "66%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-May-2021",
                "endDate": "22-Nov-2027",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Nov-2027",
                "endDate": "30-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "02-Jul-2027",
                "predictedDateU50": "12-Mar-2028",
                "phaseDuration": "0.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "30-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jun-2028",
                "predictedDateU50": "13-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Nov-2027",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the trial was expected to end in November 2027 [ <ulink linkID=\"2523131\" linkType=\"Reference\">  2523131 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "JP"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2021",
            "endDate": "12-Nov-2028",
            "statusDate": "03-May-2021",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "66%",
            "timeToRegistration": "4.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-May-2021",
                "endDate": "22-Nov-2027",
                "successPercentage": "69%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "6.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "22-Nov-2027",
                "endDate": "27-Sep-2028",
                "successPercentage": "95%",
                "predictedDateL50": "15-Aug-2027",
                "predictedDateU50": "19-Feb-2028",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "27-Sep-2028",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jun-2028",
                "predictedDateU50": "12-Nov-2028",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "22-Nov-2027",
                "milestoneExtendedDate": "",
                "notes": "In May 2021, the trial was expected to end in November 2027 [ <ulink linkID=\"2523131\" linkType=\"Reference\">  2523131 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "2380",
              "name": "Bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "03-May-2021",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "03-May-2021",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-May-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, BLA was filed in the US [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "03-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "02-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "02-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "22-Dec-2023",
                "predictedDateU50": "03-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3466",
              "name": "Metastatic bladder cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "31-May-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "09-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "07-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "07-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Dec-2023",
                "predictedDateU50": "09-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Regulatory Response",
                "status": "Positive Opinion",
                "milestoneDate": "29-Aug-2023",
                "milestoneExtendedDate": "",
                "notes": "In August 2023, the MAA was approved by the Medicines and Healthcare products Regulatory Agency in Great Britain [ <ulink linkID=\"3054005\" linkType=\"Reference\"> 3054005 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3657",
              "name": "Metastatic breast cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "30-Nov-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "30-May-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "China",
              "name": "China"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "14-Dec-2018",
            "endDate": "05-Mar-2025",
            "statusDate": "14-Dec-2018",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "90%",
            "timeToRegistration": "1.1",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 3",
                "startDate": "14-Dec-2018",
                "endDate": "10-Dec-2023",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "5.0",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "08-Jan-2025",
                "successPercentage": "95%",
                "predictedDateL50": "26-Aug-2023",
                "predictedDateU50": "08-Feb-2024",
                "phaseDuration": "1.1",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "08-Jan-2025",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "02-Sep-2024",
                "predictedDateU50": "05-Mar-2025",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "IND Filing",
                "status": "Granted",
                "milestoneDate": "02-Jun-2021",
                "milestoneExtendedDate": "",
                "notes": "In June 2021, an implied trial approval was granted for first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with carboplatin and etoposide, treatment of patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy in combination with bevacizumab, first-line treatment of adult patients with metastatic NSCLC with ≥50% of tumor cells (TC) positive for PD-L1 staining or tumor infiltration of PD-L1-positive immune cells (IC) covering ≥10% of the tumor area with epidermal growth factor receptor (EGFR) mutation-negative and anaplastic lymphoma kinase (ALK)-negative, first-line treatment for adult patients with metastatic non-squamous NSCLC with EGFR mutation-negative and ALK-negative in combination with pemetrexed and platinum-based chemotherapy in China [ <ulink linkID=\"2465366\" linkType=\"Reference\">  2465366 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, coprimary endpoints from phase III trial (NCT03735121) of atezolizumab in patients with advanced NSCLC were met [ <ulink linkID=\"2712261\" linkType=\"Reference\"> 2712261 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "CN"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "EU",
              "name": "EU"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Dec-2018",
            "endDate": "15-Mar-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.2",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "27-Dec-2018",
                "endDate": "31-Dec-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2020",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.9",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "14-Feb-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.2",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "14-Feb-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "24-Dec-2023",
                "predictedDateU50": "15-Mar-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, interim data of a phase Ib/II study (NCT03735121; IMscin001), in patients with locally advanced or metastatic NSCLC (n = 67) were reported. Atezolizumab sc (1800 mg q3w, 1200 mg q2w) showed similar exposure (cycle 1 Ctrough and AUC) as atezolizumab iv (ref, 1200 mg and 840 mg, respectively). Across cohorts, safety was comparable and no clinically significant difference in the safety profile between cohorts was observed [ <ulink linkID=\"2323072\" linkType=\"Reference\">  2323072 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, coprimary endpoints from phase III trial (NCT03735121) of atezolizumab in patients with advanced NSCLC were met [ <ulink linkID=\"2712261\" linkType=\"Reference\"> 2712261 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, MAA was filed in EU [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, the trial (NCT03735121) was expected to complete in November 2022 [ <ulink linkID=\"2125151\" linkType=\"Reference\">  2125151 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "EU"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "South Korea",
              "name": "South Korea"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "27-Dec-2018",
            "endDate": "08-Nov-2024",
            "statusDate": "31-Dec-2020",
            "phaseHighestStatus": "Phase 3",
            "probabilityOfSuccess": "88%",
            "timeToRegistration": "0.8",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 1",
                "startDate": "27-Dec-2018",
                "endDate": "31-Dec-2020",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.0",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Phase 3",
                "startDate": "31-Dec-2020",
                "endDate": "10-Dec-2023",
                "successPercentage": "93%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "2.9",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "10-Dec-2023",
                "endDate": "06-Oct-2024",
                "successPercentage": "95%",
                "predictedDateL50": "03-Sep-2023",
                "predictedDateU50": "06-Feb-2024",
                "phaseDuration": "0.8",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "06-Oct-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "23-Jun-2024",
                "predictedDateU50": "08-Nov-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "Interim Trial Results Published",
                "status": "Positive Outcome",
                "milestoneDate": "17-Sep-2020",
                "milestoneExtendedDate": "",
                "notes": "In September 2020, interim data of a phase Ib/II study (NCT03735121; IMscin001), in patients with locally advanced or metastatic NSCLC (n = 67) were reported. Atezolizumab sc (1800 mg q3w, 1200 mg q2w) showed similar exposure (cycle 1 Ctrough and AUC) as atezolizumab iv (ref, 1200 mg and 840 mg, respectively). Across cohorts, safety was comparable and no clinically significant difference in the safety profile between cohorts was observed [ <ulink linkID=\"2323072\" linkType=\"Reference\">  2323072 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Trial Endpoints Met",
                "status": "Positive Outcome",
                "milestoneDate": "02-Aug-2022",
                "milestoneExtendedDate": "",
                "notes": "In August 2022, coprimary endpoints from phase III trial (NCT03735121) of atezolizumab in patients with advanced NSCLC were met [ <ulink linkID=\"2712261\" linkType=\"Reference\"> 2712261 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Trial End Date",
                "status": "Planned",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In February 2019, the trial (NCT03735121) was expected to complete in November 2022 [ <ulink linkID=\"2125151\" linkType=\"Reference\">  2125151 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "KR"
            ],
            "probabilityOfSuccessFlag": false
          },
          {
            "company": {
              "id": "19446",
              "name": "Roche Holding AG"
            },
            "indication": {
              "id": "3665",
              "name": "Metastatic non small cell lung cancer"
            },
            "country": {
              "id": "US",
              "name": "US"
            },
            "principalCompany": {
              "id": null,
              "name": null
            },
            "designation": null,
            "startDate": "04-Apr-2022",
            "endDate": "31-Jul-2024",
            "statusDate": "30-Nov-2022",
            "phaseHighestStatus": "Pre-Reg",
            "probabilityOfSuccess": "95%",
            "timeToRegistration": "0.6",
            "failedDate": "",
            "phaseTimelines": [
              {
                "phase": "Phase 2",
                "startDate": "04-Apr-2022",
                "endDate": "30-Nov-2022",
                "successPercentage": null,
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "0.7",
                "isPredicted": false,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Pre-Reg",
                "startDate": "30-Nov-2022",
                "endDate": "01-Jul-2024",
                "successPercentage": "95%",
                "predictedDateL50": "",
                "predictedDateU50": "",
                "phaseDuration": "1.6",
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              },
              {
                "phase": "Reg",
                "startDate": "01-Jul-2024",
                "endDate": "",
                "successPercentage": null,
                "predictedDateL50": "01-Jun-2024",
                "predictedDateU50": "31-Jul-2024",
                "phaseDuration": null,
                "isPredicted": true,
                "startDateFlag": false,
                "endDateFlag": false,
                "successPercentageFlag": false,
                "predictedDate_L50_Flag": false,
                "predictedDate_U50_Flag": false
              }
            ],
            "catalysts": [
              {
                "title": "NDA/BLA Filing",
                "status": "Filed",
                "milestoneDate": "30-Nov-2022",
                "milestoneExtendedDate": "",
                "notes": "In November 2022, BLA was filed in the US [ <ulink linkID=\"2825340\" linkType=\"Reference\"> 2825340 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "PDUFA/BsUFA Date (NDA/BLA)",
                "status": "Planned",
                "milestoneDate": "15-Sep-2023",
                "milestoneExtendedDate": "",
                "notes": "In January 2023, the US FDA accepted BLA with PDUFA set date was September 15, 2023 [ <ulink linkID=\"2828976\" linkType=\"Reference\"> 2828976 </ulink> ].</para>",
                "newMilestone": false
              },
              {
                "title": "Expected Approval",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              },
              {
                "title": "Regulatory Response",
                "status": "Planned (Year)",
                "milestoneDate": "01-Jan-2024",
                "milestoneExtendedDate": "31-Dec-2024",
                "notes": "In September 2023, US approval delayed and was expected in 2024 [ <ulink linkID=\"3170649\" linkType=\"Reference\"> 3170649 </ulink>].</para>",
                "newMilestone": false
              }
            ],
            "sourceCountryIds": [
              "US"
            ],
            "probabilityOfSuccessFlag": false
          }
        ]
      }
    ]
  }